Methods for identifying arthropod repellents based on modulation of specific ionotropic receptors, and compounds and compositions identified by such methods
09910044 ยท 2018-03-06
Assignee
Inventors
Cpc classification
G01N2500/04
PHYSICS
International classification
Abstract
Provided herein are screening methods for identifying arthropod repellent compounds based on modulation of ionotropic receptors, including an Ir40a receptor, an Ir93a receptor and an Ir25a receptor. Further provided are screening systems related to these methods. Such systems may include a sample that has one or more of the ionotropic receptors; and one or more compounds that each is a repellent for at least one arthropod species, wherein the one or more compound each modulates the activity of such ionotropic receptor(s). Further provided are one or more compounds identified using the screening methods described herein, and compositions containing such compounds.
Claims
1. A method for identifying a compound that is a repellent for at least one arthropod species, comprising identifying a compound that modulates the activity of an Ir40a receptor.
2. The method of claim 1, wherein the Ir40a receptor has at least 50% sequence identity to a polypeptide encoding an Ir40a receptor from Drosophila melanogaster or an ortholog thereof.
3. The method of claim 2, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi.
4. The method of claim 1, wherein the modulation of the activity of the Ir40a receptor is determined by measuring changes in one or more electrophysiological parameters, measuring changes in calcium levels, measuring electrical potential changes, measuring changes in transcription of activity-dependent gene promoters, or any combination thereof.
5. The method of claim 1, wherein the modulation in the activity of the Ir40a receptor is an increase in the activity of the Ir40a receptor.
6. The method of claim 1, wherein the compound further modulates the activity of an Ir93a receptor, an Ir25a receptor, or a combination thereof.
7. A method of identifying a compound that is a repellent for at least one arthropod species, comprising: a) contacting an Ir40a receptor or Ir40a receptor-expressing neuron with a candidate compound; b) measuring the activity of the Ir40a receptor; c) comparing the activity of the Ir40a receptor after contact with the candidate compound to the activity of the Ir40a receptor in the absence of the candidate compound; and d) identifying a compound that is a repellent for at least one arthropod species by determining whether or not the candidate compound modulates the activity of the Ir40a receptor.
8. The method of claim 7, wherein the Ir40a receptor has at least 50% sequence identity to a polypeptide encoding an Ir40a receptor from Drosophila melanogaster or an ortholog thereof.
9. The method of claim 8, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi.
10. The method of claim 7, wherein the Ir40a receptor is provided with a co-receptor or chaperone protein, or wherein the Ir40a receptor-expressing neuron further expresses a co-receptor or chaperone protein.
11. The method of claim 7, wherein the activity of the Ir40a receptor is measured by one or more electrophysiological parameters, calcium levels, electrical potential, transcription of activity-dependent gene promoters, or any combination thereof.
12. The method of claim 7, wherein the modulation of the activity of the Ir40a receptor is an increase in the activity of the Ir40a receptor.
13. The method of claim 7, wherein, in step (a), the candidate compound further contacts an Ir93a receptor, or an Ir25a receptor, or a combination thereof.
14. A method of identifying a compound that is a repellent for at least one arthropod species, comprising: a) providing a sample comprising a full-length or partial Ir40a receptor protein from Drosophila melanogaster or an ortholog thereof; b) contacting the sample with a candidate compound; c) measuring the activity of an Ir40a receptor in the sample; d) comparing the activity of the Ir40a receptor after contact with the candidate compound to the activity of the Ir40a receptor in the absence of the candidate compound; and e) identifying a compound that is a repellent for at least one arthropod species by determining whether or not the candidate compound modulates the activity of the Ir40a receptor.
15. The method of claim 14, wherein the Ir40a receptor has at least 50% sequence identity to a polypeptide encoding an Ir40a receptor from Drosophila melanogaster or an ortholog thereof.
16. The method of claim 15, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi.
17. The method of claim 14, wherein the sample further comprises a co-receptor or chaperone protein.
18. The method of claim 14, wherein the activity of the Ir40a receptor is measured based on one or more electrophysiological parameters, calcium levels, electrical potential, transcription of activity-dependent gene promoters, or any combination thereof.
19. The method of claim 14, wherein the modulation of the activity of the Ir40a receptor is an increase in the activity of the Ir40a receptor.
20. The method of claim 14, wherein the sample further comprises (i) a full-length or partial Ir93a receptor protein from Drosophila melanogaster or an ortholog thereof; or (ii) a full-length or partial Ir25a receptor protein from Drosophila melanogaster or an ortholog thereof, or a combination of (i) and (ii).
21. A system, comprising: a) a sample comprising an Ir40a receptor or Ir40a receptor-expressing neuron; and b) one or more compounds that each is a repellent for at least one arthropod species, wherein the one or more compounds each modulates the activity of the Ir40a receptor.
22. The system of claim 21, wherein the Ir40a receptor has at least 50% sequence identity to a polypeptide encoding an Ir40a receptor from Drosophila melanogaster or an ortholog thereof.
23. The system of claim 21, wherein the sample further comprises a co-receptor or chaperone protein.
24. The system of claim 21, wherein the sample further comprises (i) an Ir93a receptor or the neuron co-expresses Ir40a receptor and Ir93a receptor; or (ii) an Ir25a receptor or the neuron co-expresses Ir40a receptor and Ir25a receptor, or a combination thereof.
25. A system for screening a plurality of candidate compounds, comprising: a) a sample comprising an Ir40a receptor or Ir40a receptor-expressing neuron; and b) a plurality of candidate compounds, wherein at least one of the candidate compounds is a repellent for at least one arthropod species, and wherein the at least one repellent compound modulates the activity of an Ir40a receptor.
26. The system of claim 25, wherein the Ir40a receptor has at least 50% sequence identity to a polypeptide encoding an Ir40a receptor from Drosophila melanogaster or an ortholog thereof.
27. The system of claim 25, wherein the sample further comprises a co-receptor or chaperone protein.
28. The system of claim 25, wherein the sample further comprises (i) an Ir93a receptor or the neuron co-expresses an Ir40a receptor and an Ir93a receptor; or (ii) an Ir25a receptor or the neuron co-expresses an Ir40a receptor and an Ir25a receptor, or a combination of (i) and (ii).
Description
DESCRIPTION OF THE FIGURES
(1) The present application can be best understood by references to the following description taken in conjunction with the accompanying figures.
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
DETAILED DESCRIPTION
(12) The following description is presented to enable a person of ordinary skill in the art to make and use the various embodiments. Descriptions of specific materials, techniques, and applications are provided only as examples. Various modifications to the examples described herein will be readily apparent to those of ordinary skill in the art, and the general principles defined herein may be applied to other examples and applications without departing from the spirit and scope of the various embodiments. Thus, the various embodiments are not intended to be limited to the examples described herein and shown, but are to be accorded the scope consistent with the claims.
(13) Screening Methods
(14) Provided herein are screening methods for identifying one or more compounds that are repellents for at least one arthropod species. Changes in the activity of one or more of an Ir40a receptor, an Ir93a receptor, and an IR25a receptor can be used to identify whether or not one or more compounds are arthropod repellents. Such methods can help with identifying new repellants to fight insect-borne diseases and plant pests.
(15) Ionotropic receptor 40a (also known as Ir40a), Ionotropic receptor 93a (also known as Ir93a), and Ionotropic 25a (also known as Ir25a) are ionotropic receptors present in arthropods. Ionotropic receptors are a broad class of transmembrane receptors that form ion channel pores in cell membranes, such as neurons. Although ionotropic receptors exist in large gene families with multiple members, each individual member of this receptor family may have specificity for certain compounds to which each unique receptor may bind to or interact with.
(16) Perception of a compound by an ionotropic receptor can modulate the physical status of the ion channel, and may result in a change in the flow of various ions, such as Na.sup.+, Ca.sup.2+, K.sup.+, and Cl.sup., into or out of the cell. The candidate compound screened by the methods described herein may increase or decrease the flows of various ions. The modulation of the Ir40a receptor may be direct or indirect. For example, such modulation may result from a candidate compound acting as a ligand binding to the Ir40a receptor or certain portions thereof. Such modulation may also result from a candidate compound acting as an agonist of the Ir40a receptor, for example, causing activation of the neuron downstream of the Ir40a receptor.
(17) In some embodiments, the method includes: a) contacting an Ir40a receptor, an Ir93a receptor, and/or an Ir25a receptor, or Ir40a receptor-expressing neuron, Ir93a receptor-expressing neuron, and/or Ir25a receptor-expressing neuron with a candidate compound; b) measuring the activity of the receptor; c) comparing the activity of the receptor after contact with the candidate compound to the activity of the receptor in the absence of the candidate compound; and d) identifying a compound that is a repellent for at least one arthropod species by determining whether or not the candidate compound modulates the activity of the receptor.
(18) In other embodiments, the method includes: a) providing a sample that includes an Ir40a receptor, an Ir93a receptor, and/or an Ir25a receptor; b) contacting the sample with a candidate compound; c) measuring the activity of the receptor in the sample; d) comparing the activity of the receptor after contact with the candidate compound to the activity of the receptor in the absence of the candidate compound; and e) identifying a compound that is a repellent for at least one arthropod species by determining whether or not the candidate compound modulates the activity of the receptor.
(19) The method may also include the use of one or more of Ir40a receptors, Ir93a receptors, and Ir25a receptors, either alone or in any combination, in a screening method for a compound that modulates the activity of one or more of an Ir40a receptor, an Ir93a receptor, and/or an Ir25a receptor. It is to be understood that in embodiments that include all three of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor, that these receptors may form a heterotrimer. In some embodiments, the method involves identifying a compound that modulates the activity of an Ir40a receptor. In some embodiments, the method involves identifying a compound that modulates the activity of an Ir93a receptor. In some embodiments, the method involves identifying a compound that modulates the activity of an Ir25a receptor. In some embodiments, the method involves identifying a compound that modulates the activity of an Ir40a receptor and an Ir93a receptor. In other embodiments, the method involves identifying a compound that modulates the activity of an Ir93a receptor and an Ir25a receptor. In some embodiments, the method involves identifying a compound that modulates the activity of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor. The method may involve the use of an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with an Ir40a receptor.
(20) With reference to
(21) The cell provided in method 100 may be, for example, a neuron or an oocyte. In a particular embodiment, the Ir40a receptor is expressed in an Ir40a+ neuron. While method 100 uses a cell that expresses the Ir40a receptor from Drosophila melanogaster, it should be understood that in other exemplary embodiments, the Ir40a receptor may be provided in other forms. For example, the method may use an organism that expresses an Ir40a receptor. The organism may be an arthropod, such as an insect. An example of a suitable organism is Drosophila melanogaster. The method may also use a sample containing a full-length or partial Ir40a receptor protein from Drosophila melanogaster or an ortholog thereof may be provided, or a sample containing an organism expressing an Ir40a receptor, a cell expressing an Ir40a receptor, or an isolated Ir40a receptor.
(22) The Ir40a receptor provided in a cell, an organism, or a sample may be an endogenous receptor or a recombinant receptor. For example, a Drosophila melanogaster cell may express an endogenous Ir40a receptor, or an Ir40a receptor encoded by Aedes aegypti. In some embodiments, recombinant may refer to a polynucleotide or a polypeptide wherein the exact nucleotide sequence of the polynucleotide or amino acid sequence of the polypeptide is foreign to (not naturally found in) a given host. In other embodiments, recombinant may refer to a polynucleotide sequence naturally found in a given host, but in an unnatural context, such as if the polynucleotide includes two or more subsequences that are not found in the same relationship to each other in nature. For example, regarding the latter, a recombinant polynucleotide could have two or more sequences from unrelated polynucleotides or from homologous nucleotides arranged to make a new polynucleotide. With reference to a host genome, the polynucleotide sequence that encodes the Ir40a polypeptide is recombinant.
(23) The Ir40a receptor provided in a cell, an organism, or a sample may also be modified. Modified Ir40a receptors may include sequence information that is endogenous to or recombinant to the organism. For example, Drosophila melanogaster may express an endogenous or recombinant Ir40a receptor with a GFP reporter sequence attached to the receptor polypeptide.
(24) With reference again to
(25) With reference again to
(26) With reference again to
(27) Based on the data gathered in step 108 regarding the change in activity of the IR40 receptor, the ability of the candidate compound to act as a repellent is determined in step 110. A candidate compound may be selected as a repellent if modulation in activity of the Ir40a receptor the presence of the compound is statistically significant compared to the absence of the compound, compared to a control, or a combination thereof. Various statistical tests are known in the art for determining whether a quantitative value is significantly different from another quantitative value, such as the Student's t-test. In one embodiment, an increase in Ir40a receptor activity may indicate that the candidate compound is a repellent. In another embodiment, a decrease in the activity of the Ir40a receptor may indicate that the candidate compound is a repellent.
(28) The components and techniques described in exemplary method 100 of
(29) The exemplary method outlined in
(30) Variations of the Ir40a Receptor
(31) Homologs and Orthologs
(32) A homolog or an ortholog or any known or putative Ir40a receptors may also be used in the methods and systems described herein. A homolog may be a protein whose nucleic acid sequence that encodes that protein has a similar sequence to the nucleic acid sequence that encodes a known or putative Ir40a receptor, or a protein whose amino acid sequence is similar to the amino acid sequence of a known or putative Ir40a receptor. Ir40a homologs may have functional, structural or genomic similarities to any known or putative Ir40a receptor. One of skill in the art would recognize the techniques that may be employed to clone homologs of a gene, using genetic probes and PCR. Homologs can also be identified by reference to various databases and identity of cloned sequences as homolog can be confirmed using functional assays and/or by genomic mapping of the genes. Additionally, one of skill in the art would understand that an ortholog is an evolutionarily-related polypeptide or polynucleotide sequence in different species that have similar sequences and functions, and that develop through a speciation event.
(33) In some embodiments, a homolog and/or ortholog of an Ir40a receptor is a protein whose nucleic acid sequences have at least 30%, 40%, 50% 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the nucleic acid sequence encoding any known or putative Ir40a receptor. In another embodiment, a homolog of an Ir40a receptor is a protein whose amino acid sequence has at least 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence encoding any known or putative Ir40a receptor.
(34) The Ir40a receptor may be from one or more arthropod species. For example, in certain embodiments, the Ir40a receptor is a homolog or ortholog of the Ir40a receptor from Drosophila melanogaster. In some embodiments, the Ir40a receptor has at least 50, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide encoding an Ir40a receptor from Drosophila melanogaster.
(35) While Drosophila melanogaster is one reference point for homology, it should be understood that other known or putative receptors may serve as reference points for homology to the Ir40a receptor. For example, known or putative Ir40a receptors may include [GI:281365361, Accession NP_610140, ionotropic receptor 40a, Drosophila melanogaster], [GI:193904091, Accession EDW02958, ligand-gated ion channel, Drosophila grimshawi], [GI:333469626, Accession EAA13593, ligand-gated ion channel, Anopheles gambiae], [GI:167870272, Accession EDS33655, ionotropic glutamate receptor-invertebrate, Culex quinquefasciatus], [GI:40909715, Accession CK525472, predicted protein BGIBMGA010939-TA, Bombyx mori], [GI:270013267, Accession EFA09715, hypothetical protein TcasGA2_TC011848, Tribolium castaneum], [GI: 328712650, Accession XP_001949860, predicted glutamate/NMDA receptor subunit 1-like, Acyrthosiphon pisum], [GI:212510105, Accession EEB13339, glutamate receptor U1 precursor, putative, Pediculus humanus], and [GI:321470562, Accession EFX81538, hypothetical protein DAPPUDRAFT_102366, Daphnia pulex]. Each sequence associated with the foregoing accession numbers is incorporated herein by reference.
(36) In other embodiments, the Ir40a receptor has at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide encoding an Ir40a receptor from an ortholog of Drosophila melanogaster. Such orthologs may include, for example, Aedes aegypti Aaeg (AAEL014270), Anopheles gambiae Agam (AGAP004021), Culex quinquefasciatus Cqui (CPIJ009722), Acyrthosiphon pisum (Pea aphid) Apim (ACYPI20767), Bombyx mori (Silkmoth) Bmor (BGIBMGA010939), Pediculus humanus (Human body louse) Phum (PHUM235670).
(37) The amino acid sequences of the Ir40a receptor from Drosophila melanogaster and some orthologs thereof are provided in Table 1 below.
(38) TABLE-US-00001 TABLE1 AminoacidsequencesoftheIr40areceptorfrom Drosophilamelanogasterandorthologsthereof ArthropodSpecies AminoAcidSequence DmelIr40a MHKFLALGLLPYLLGLLNSTRLTFIGN (Drosophila DESDTAIALTQIVRGLQQSSLAILALP melenogaster) SLALSDGVCQKERNVYLDDFLQRLHRS NYKSVVFSQTELFFQHIEENLQGANEC ISLILDEPNQLLNSLHDRHLGHRLSLF IFYWGARWPPSSRVIRFREPLRVVVVT RPRKKAFRIYYNQARPCSDSQLQLVNW YDGDNLGLQRIPLLPTALSVYANFKGR TFRVPVFHSPPWFWVTYCNNSFEEDEE FNSLDSIEKRKVRVTGGRDHRLLMLLS KHMNFRFKYIEAPGRTQGSMRSEDGKD SNDSFTGGIGLLQSGQQADFFLGDVGL SWERRKAIEFSFFTLADSGAFATHAPR RLNEALAIMRPFKQDIWPHLILTIIFS GPIFYGIIALPYIWRRRWANSDVEHLG ELYIHMTYLKEITPRLLKLKPRTVLSA HQMPHQLFQKCIWFTLRLFLKQSCNEL HNGYRAKFLTIVYWIAATYVLADVYSA QLTSQFARPAREPPINTLQRLQAAMIH DGYRLYVEKESSSLEMLENGTELFRQL YALMRQQVINDPQGFFIDSVEAGIKLI AEGGEDKAVLGGRETLFFNVQQYGSNN FQLSQKLYTRYSAVAVQIGCPFLGSLN NVLMQLFESGILDKMTAAEYAKQYQEV EATRIYKGSVQAKNSEAYSRTESYDST VISPLNLRMLQGAFIALGVGSLAAAAL NNTINVRSLNSRDKFICGGPVKIWYYL VLLLWYYFNRGLVGIYQLWHKTSIRNT GKGMPFLGE(SEQIDNO:1) AaegIr40a MNKVLATPASKADKLESLISIGLVVQN (Aedesaegypti) LCSQLQSMRMEAHLSNPSLLQELVDKL PANIKLHWALHQRQVPVVDFRAFTYHA HLAPLPDLSNHSGMVLGLSEMINLLAP KTLAILVLKETKIDKIDRLTVMIHHHN IPTCIFNNQDEYFQYIGNNLKKSLETT SLLFCHPEEMLGELIDRRLAHRLSLYI FYWGARKAPTNLDRSLMREPLRVAVIT NPRKNIFRIFYNQAKPNNRGELLSANW FDGNDMTFQKVPLLPTPTTVYKNFEGR VFTIPVIHKPPWHFVTYRKVNESSLNE TDVDQLELSANGTDNEQLEVFEVTGGR DHNLIQLIAHRMNFSFKYVDQEDRIQG TAVGPPENAIFTGALGMLQRREVDLFL GDVAVTWERMQAVEFSFFTLADSAAFV THAPRKLSEALALVRPFQVAVWPLVLL TIMMSGPILYMIIAMPYRLEDWARGTM ARRRRFKVQRGPAFYHMQYIQEMNYGT LPGGTEIAGTPRHPSLDRCIWYTINVY LRQSATIPYNGHVSRFFSILLWLCATY VLGDVYSAQLTSQLARPAREGPIDTLG KLEVFMERDGYQLLVERQSAFQAALVN STGILQRLYRITQRQSHNESYLVSSVE EGIRILVDNSKRAVFGGRETLYFNTKR YGAHRFQLSEKLYTRYSAVAVQFGSPF LDSLNEVIMRLFEAGIIEKITIAEYER MFGSQLGQFGDESAKTTKPESSETEGG KSKKSTESNEKLQPMNLRMLQGAFLAL ACGHLLGVLTLVLENKTKCIQISFGWI KAWLHRIGLIFCKLGKAVWRSWRRLHN DD(SEQIDNO:2) AgamIr40a MGVGSNSKYILALVLLRVALVWGAFPT (Anophelesgambiae) QRNLIALYERSNQSGMIRGISEMVNLL APKSLVILVQNETKIDRLDKLTVMIHH HNIPTCVYYDLEAYFSLIEENLKKSLE ITSLIFCHPEDMLQDITDRRLAHRLSL FIFYWGAAQLPPTLNPNLLMEPFRVAI ITNPRRNIFRIFYNQAKPNNRGDMLSV NWFDGNDMTFKRVPLLPSPTEVYKNFE GRIFTIPVIHKPPWHFIVYGNGSASVG DNQNSSSSDAAGGFELELDENVTVESD DTYFTVKGGRDHNLMQLIAERMNFTFQ YVEPPEKIQGIALGSEDNASFSGALGM LQRREVELYLGDVAVTWERMKAVEFSF FTLADSAAFVTHAPRKLNEALALVRPF QITVWPPVIITILISGPILYIIISTPY RWRSAQTVHARNARWRPTRSRLRKPAF YNLRYIEEMSYTRFRAERTSLINNHHH SRGQDYPSLDRCIWYTINVYLRQSANI PFDGHLARFFSILLWLCATYVLGDVYS AQLTSQLARPARESPINTLGRLENRMN REGYQLLVERQSAFHAALVNSTGVLQR LYRLTRQRSVNDSFLVKSVEEGIRVLQ ADPKYAVFGGRETLYFNTKRYGANRFQ LSEKLYTRYSAVAVQIGCPFLDSLNEV IIVIRLFEAGIVEKITIAEYEQMFGRQ KGGVSHAEETVRTVKSTNSECDTDGTG SGKRKTDSNDKLQPMNLRMLQGAFLVL ACGHLLGGICLFIERHMGMINPCGDTL RQGWRHLNRVVRKLGRGGSFKTQSN (SEQIDNO:3) CquiIr40a MKVGIVWCLFVLLGRSFVQAYHSQLVP (Culex IADPSNHSGMVTGLSEMINLLSPKTLV quinquefasciatus) LLVLNETKIHKIDRLTVAIHSYNIPTC IFYDLEQYFEYIANNLKNSLDTTSLLL CHPADMLVDLVDRRLAHRLSLYIFYWG ARRLPAGFDRALLREPLRVAVITNPKK KIFRIFYNQAKPNNLGELLSANWFDGS DMTFKRVPLLPTPTEVYKNFEGRVFTI PVIHKPPWHFLTYTNLNESCNDTDTEF DMANVTSFQVTGGRDHNLMQLIAARMN FTFRYIEPEEKIQGTAMGSGDNVSISG ALGMLQRREVDLFLGDVAVTWERMQAV EFSFFTLADSAAFVTHAPRKLSEALAL VRPFQVTVWPLVIFTIILSGPVLYLII AMPFRLEDWMKGTLDKARRLQVRRGPP FYDMQYIREMGYGLVPRADIAGTPQHP SLNRCVWYTINVYLRQSATIPYNGHVA RFFSILLWLCATYVLGDVYSAQLTSQL ARPAREGPINTLGKLEELMESPGGGYQ LLVERQSAFQVALANSTGILQRLYRIT QRHPDNESYLVGSVEEGIQILLVNSKR AVFGGRETLYFNTKRYGAHRFQLSDNL YTRYSAVAVQFGSPFLDSLNEVIMRLF EAGIIGKITVAEYERMFGSKSGGQFAD ETVESTKSDDGVDATGKAKKSAESSEK LQPMNLRMLQGAFLALGFGHSVGAIIL LVENQLKGIKSVYQRVLGVLTRTGRVV RKIWTAIRRSL(SEQIDNO:4) ApisIr40a IYIFFLIRSTIYYVSFSGRDIFKNTVA (Acyrthosiphon SAICNEYSIVVLTNXNANIIMLILINI pisum) IFISLYLSSSIILIDYNTYLIIQNLLV NVTIYINIYRLLGLHRDGDFLFFTQIR RSNLMSRNVVYVFLWLRSSVSRTFKAD ILEAMRVCVITSPRPGFYQIYYSQASA RPGYGSSLKMVNWWSAMDGLVRFPLLP PPKQVYKNFEGRYFNVPVLHKPPWTFV EYLNDSFRVEGGRDDKLINLLADKLHF QFKYIDPPDRTQGSGLDRGSSMQGVLG LIWQREADWFVGDLSITYERNLVVDFS FLTLVDNEAFLTHAPGRLNEAFSLIRP FHWSVWPLLLITVIFAGPILYILVDTT DGHPQGKSMLYWKCVWWSVTVFLQQAA IIPSENNKIRFVAGLLMLSVTYVIGDM YSASLTSILARPPKEPPINTLKELSEA MRDSGLQLLVEVQSASQAMLENGTGVY EELSQLVTRQREYLIGSTEKGMQLVRD NKNYAVIGGRETFYYDIKRFGAQHFHL SEKLNTRYSAIAFQRACPYRDNFDDVL MRLFEGGILSKITEEEYQKLNDKLMGS EEFDSTSVVIEPVLEGSEPRQEDDDKQ LTIAMSMKTLQGAFYVLAIGSILAGLL LLIEMRSHDKLEKDKVIKLVEAPFVYK RKVPNKFQNRLYDLK (SEQIDNO:5) BmorIr40a MTKLPKDFNVAIKDIAESLPSKEMTVV (Bombyxmori) RGNSTNIRSQDVFELLRLLCQHNIQVV NLDIAAMENKEMYYGYLKKALDVSDER TNLILCEPYECENLLLELRENNLIHRT ILYIFFWPYGSVSDRFLNTMVEAMRVA VITNPRESVFRIYYNQATPNRLNHLSL VNWWAFRLYKSPLLPSADKVYKNFRGR VFDVPVLHAPPWHFVKYNNDSSINVTG GRDDKLLKLIANKLNFRYRYYDPPDRS QGSGIIGNGTFKGTLGLIWKRQADFFL GDVTMTWERLQAVEFSFLTLADSGAFL THAPAKLSETLAIIRPFRWEVWPLVCA TLFITGPALWIVIAAPSLWQRKKRDQM GLLNNCCWFTVTLFLRQSSTKEPSSTH KARLVTVLISLGATYVIGDMYSANLTS LLARPAKEPPIGTLPALEEAMREHGYE LVVESHSSSLSILENGTGVYGRLAKLM KRQRVQRVHNVEAGVRLVLNRRRVAVL GGRETLYYDTERFGSHNFHLSEKLYTR YSAIAFQIGSPYLETINNVVMTLFEAG ILGKMTTDEYKNLPEQSRRSEPVTESE NLSTEKTGETAAVTQIQNETSKGLEPV SLTMLRGAFCLLGIGHLLAGVTLLIEI QLYRRARKRALPPQTRNPTNTFKAKAK KCILRGWRRIKAAAILAIDRALAPDRG ID(SEQIDNO:6) TcasIr40a MRRDHGGDLVSASFDIVAGFLFEEICI (Triboliumcastenium) CFDKNTNINFLQHLLVRFVSNNIAIKL FNITTVEVQDKYFAFLNYQVTNHLGAN TIFFSSHKFYEHVLLEINERDFIRRNL IYIFNWGRRPFSRYFVRNIINVMKVFV ITNPRNDTFRIFYNQAVPYKKHHLEMV NWWQHGVGLFNHPTLPAKYNNVFKDFK ENVFKIPVIHKPPWHFVQYGNDSIKVT GGRDDRILSLLSKKLNFRYDYFDPPER IQGSSASENGTFKGVLGLIWKRQAEFF IGDVALSHERANYVEFSFITLADSGAF ITHAPSKLNEALALLRPFQWQVWPAIG VTFVVVGPVLYAIIALPNAWRPRFRVR SHARLFFDCTWFTTTVLLKQTGKEPSS SHKARFFIIILSISSTYVINDMYSANL TSLLAKPGREKAINNLNQLEKAMATRG YDLYVERHSSSYSLFENGTGIYSRLWQ MMNRRQTHFLLESVEEGVQLVRDSTNK AVIAGRETLFFDIQRFGASNFHLSEKL NTAYSAIALQLGCPYIEEINKILMAIF EAGIITKMTENEYEQLGKKKQTTSETE KELIPGVKKENRRVAKVSEDNEKLQPI SIKMLQGTFYLLCIGNIFSGFILLAEI LVYKHRKTYKHKKRRHRFVYLRKIRHS VASKFGAVVDAVRRVYRRAMHDAFVAT LEYLE(SEQIDNO:7) PhumIr40a TPTFCFSYMKIFFFLFNFGGIIIRGHH (Pediculushumanus) LTENDFDDDEDMMMSLSLAVKDIIIGL PSSHVTLLFENITDSTFPMILSKTLQK SLITTSIYTIEKGENQKEVEQEDLMHR KILYILYRDHNLRDNDFFSGQFEAMRI SLLTKTQNGMFVRYKFFLKIFFFFFFL ENLIYNRSTRFFSDDKLLTIIAQKLNF RYKYVDPPERLQGTGIFTNGTFSGVLG QVWQREFDFFMGDVTITYDRAKTVEFT FFTLVDSEAFVTHRPSKLNEAFALIRP FQWQVWPPILCTFTIYGPILFFIIESQ NYLMKIKRDSKERKKLFFHCVWFSIST FLKQGGIYPSKSHKVRLLLIIVTLAAT YVIGDMYSANLTSLLARPGREKPITVL EQLDTAMETRGYQLLVEKHSSSLTTLQ NGTGIYEKIWEKMKNQKNYLIESVESG MKMVRKNKNIVILGGRETLYFDSRRFG SYNFQMSEKLNTRYAGIAMQLGCPYIE NFNKILMQLFEGGILTKMTVEEYERLG EEQRAEFENVKKKKNVSQIKNEDIQVS TTHALQPLNTKMLQGAFYILFIGYLLS GFTLFLEIQFENICRFLKLIKCHPFIK SIKFNKFFNKIYRKKF (SEQIDNO:8) PpapIr40a MCYLSENSDQENELMIGLVEIVKSLDI (Phlebotomus KNLVIFLPTENSTYDIDKFIMRVHERQ papatasi) LQSVIFFNPDDYYNHIAQCKSDSVETT SLIFSEPREIVREIQERILDHRLNLFM FYWGSHGLPKRGQLCLKEPMKVVILTT PRQNIYYNQATPDGNGTLTLVNWYDGN SLGLFKVPVLPSPSQVYQNFRERVFYI PVIHSPPWHFVIYRNESSDNETFPMEE YDDMDISFKVIGGRDDSLLQLLAKKMN FKYEYIDPPERTQGSAFGSNDNLSFSG GLGLLQRREANLLLGDIAITSERSKAV EFSFFTLVDSGAFVTHAPRRLSEALAL VRPFRLNVWPALIITSLSGPVLYLVII MPQWWRKSSQKEKENRDSFHHIDYIEE MNYGVPRRRIQAMKFTKRKELPQNLLG RQFLVDRCVWFTINLFLKQSACLPYGG NRARFVSSILWLSATYILGDFYSAQLT SQLARPAREAPINDLYRLEAAMKWKGY ELYVERQSASLAILENGTEIFHRLHLM MMAQNRKSNESYLISSIEEGVHMVMMG DRKVVLGGRETLFFNIKRYGMKKFQLS EKLYTRYSAVAVPNGCPFLDSLNKVYV TFFFHKIMHLFEGGILDRMTNEEYEKM FNSIKFKTPKEEVDKTTKKSNKEVPQE EHLLKPVSLKLLQGAFYTLLIGYILSG IVLLLESGKSPEGIAQRQLPGAISVCI YMKIIIAKCFSFIAEEIYDCFKDDEDD E(SEQIDNO:9)
(39) One of skill in the art would recognize the methods and techniques that may be employed to determine the percent identity between two amino acid sequences, or between two nucleic acid sequences. One of skill in the art would also recognize that the sequences can be aligned for optimal comparison purposes. For example, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions can then be compared. Methods of comparing nucleic acid or amino acid sequences are well-known in the art.
(40) Variations of the Ir93a Receptor
(41) Homologs and Orthologs
(42) A homolog or an ortholog or any known or putative Ir93a receptor may also be used in the methods and systems described herein. A homolog may be a protein whose nucleic acid sequence that encodes that protein has a similar sequence to the nucleic acid sequence that encodes a known or putative Ir93a receptor, or a protein whose amino acid sequence is similar to the amino acid sequence of a known or putative Ir93a receptor. Ir93a homologs may have functional, structural or genomic similarities to any known or putative Ir93a receptor.
(43) In some embodiments, a homolog and/or ortholog of an Ir93a receptor is a protein whose nucleic acid sequences have at least 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the nucleic acid sequence encoding any known or putative Ir93a receptor. In another embodiment, a homolog of an Ir93a receptor is a protein whose amino acid sequence has at least 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence encoding any known or putative Ir93a receptor.
(44) The Ir93a receptor may be from one or more arthropod species. For example, in certain embodiments, the Ir93a receptor is a homolog or ortholog of the Ir93a receptor from Drosophila melanogaster. In some embodiments, the Ir93a receptor has at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide encoding an Ir93a receptor from Drosophila melanogaster.
(45) While Drosophila melanogaster is one reference point for homology, it should be understood that other known or putative receptors may serve as reference points for homology to the Ir93a receptor. For example, known or putative Ir93a receptors may include Mayetiola destructor\Mdes015305, Aedes aegypti Aaeg\AAEL005012, Anopheles gambiae Agam\AGAP000256, Culex quinquefasciatus Cqui\ CPIJ009222, Heliconius melpomene\HMEL002270, Manduca sexta\Msex000431, Bombyx mori (Silkmoth) Bmor\BGIBMGA010960, Tribolium castaneium\TC000374, Atta cephalotes\ACEP27701, Acromyrmex echinatior\AECH20041, Solenopsis invicta\SINV12854, Pogonomyrmex barbatus\PB25907, Camponotus floridanus\CFLO19836, Linepithema humile\LH25937, Harpegnathos saltator\HSAL21373, Apis mellifera\GB42136, Apis mellifera\GB50521, Megachili rotundata\MROT 00005973, Nassonia vitripennis\Nasvi2EG001464, Acyrthosiphon pisum (Pea aphid) Apim\ACYPI20767,ACYPI43510, Rhodnius prolixus\RPTMP07829, Pediculus humanus (Human body louse) Phum\PHUM513120, Tetranychus urticae\tetur02g05540, and Ixodes scapularis\ISCW007957. Each sequence associated with the foregoing accession numbers is incorporated herein by reference.
(46) Further, the amino acid sequences of the IR93a receptor from Drosophila melanogaster and some orthologs thereof are provided in Table 2 below.
(47) TABLE-US-00002 TABLE2 AminoacidsequencesoftheIR93areceptorfrom Drosophilamelanogasterandorthologsthereof ArthropodSpecies AminoAcidSequence DmelIR93a MNPGEMRPSACLLLLAGLQLSILVPTEANDFSSFLSANASLA (Drosophila VVVDHEYMTVHGENILAHFEKILSDVIRENLRNGGINV melenogaster) KYFSWNAVRLKKDFLAAITVTDCENTWNFYKNTQETSILLIA ITDSDCPRLPLNRALMVPIVENVEENALLVKSIVHESI TNHITPISLILYEINDSLRGQQKRVALRQALSQFAPKKHEEMR QQFLVISAFHEDIIEIAETLNMFHVGNQWMIFVLDMV ARDFDAGTVTINLDEGANIAFALNETDPNCQDSLNCTISEISL ALVNAISKITVEEESIYGEISDEEWEAIRFTKQEKQA EILEYMKEFLKTNAKCSSCARWRVETAITWGKSQENRKFRST PQRDAKNRNFEFINIGYWTPVLGFVCQELAFPHIEHHF RNITMDILTVHNPPWQILTKNSNGVIVEHKGIVMEIVKELSRA LNFSYYLHEASAWKEEDSLSTSAGGNESDELVGSMTF RIPYRVVEMVQGNQFFIAAVAATVEDPDQKPFNYTQPISVQK YSFITRKPDEVSRIYLFTAPFTVETWFCLMGIILLTAP TLYAINRLAPLKEMRIVGLSTVKSCFWYIFGALLQQGGMYLP TADSGRLVVGFWWIVVIVLVTTYCGNLVAFLTFPKFQP GVDYLNQLEDHKDIVQYGLRNGTFFERYVQSTTREDFKHYL ERAKIYGSAQEEDIEAVKRGERINIDWRINLQLIVQRHF EREKECHFALGRESFVDEQIAMIVPAQSAYLHLVNRHIKSMF RMGFIERWHQMNLPSAGKCNGKSAQRQVTNHKVNMDDM QGCFLVLLLGFTLALLIVCGEFWYRRFRASRKRRQFTN(SEQ IDNO:10) AaegIR93a MLPRLKWLVLVLVVCKLDHSRGDDFPSLISANASIAVILDRE (Aedes YLDAQYDDILEGTKRLFERILRDNFRNGGLIVKYFSWT aegypti) SINLRRDFTAVLSISNCENTWDVYKNAAKENLVIMSITDSDCL RLPLNNAIMVNLKSIVALSKESEDVRPLSLSLFRIES HTHMWEKRKAIRKVLVNLPTRYIGRNFIAIITTQTMELVMEIA KELRMVTPLAQWLYVVSDTSADRNNISAVHPIISEGD NIAFVYNLRRNAQSCESHMLCYVENLITSLVHGLSKLIREEK AVYGQIADEEWEVIRMTKAERKDEILKIMRSDLIGKDS CNECSMWKVEAGETWGYTYQSAADELLTGVMSTHRKQISL LDVGYWTPQDGFVMRDNMFPHVADGFRGVHLNFYSYHNPP WQFVTYNESGHLSLSRGVVMDILTELSRKLNFTFNILISQTNL EYIGNMTDDANNTINRDAHSITTDIPNEILRSLMDNK ILLAAVGATVSPKQKKYVNFTTPISIQTYSFIVSRPKELSRVFL FLSPFTIDTWLCLSATVLLMGPFLYVVNRLSPFYEH HGRSNTIGLGKLYNCFWYIYGALLQQGGLYLPYADSGRIIIGT WWLVVLVIVTTYCGNLVAFLTFPKIAIPITTVNQLIR NEQGVSWSIRRGTFLEQFLQETDDPKYIKLHNHAGYVSEESE QMVERIRTGRHVHIDWRTNLKYLMKKEFLKNDRCDFAL SVDEFLDEQIALAMPKNSPYLELINAELTKMHQFGFIQRWLG SYMPSEDKCSNARKSTEVENHTVNNDDMAGSYYVLMIG FSMGLFMFVLEYGWRWYKRSKEETLQPFTE(SEQIDNO:11) AgamIR93a MVLRLVGLWSILLLLLLLLVLRPDPAVGDDFPSLLSTNASMG (Anopheles KLNITPLLSIILDREYLGADYERTLDETKNVVEKLIRE gambiae) HLKNGGLIVKYYSWTSINLKRDFSAVLSVSSCKNTWDIYQEA VRERLVMLSITDPDCPRLPTNNAIMIPRSDGSGSNAFD EVSQIILDMKSSRAINWHTATLLYDQVYDAEISRCILSLLEDR EGIKPLTLTEFKINAPTHSWEKRKEIRRTLLGIPTAY TGRNFIAIVNIATLTLLMEISKDLKLVNPFAQWLYLIPNTEKA NSNFTTRSTLINEGDNVAFVYNSGSKAQNCTVSVLCY IESYLLHFIRSLSKLIREEQVVFGQISDEEWEIIRPSKQERKTKF LQMIKAAITSKDECNKCSQWKIQSAETWGYVYRTD FLTDGADLQERRKYTMLDIGYWSPQDGFMLTDALFPHTQYG FRGVQLIFYSYHNPPWQFVAYNDSGSPVISSGVVYDILN ELSRKLNFTYTMVISQPAEINGSLVEGNTSSVYDLKTISSDIPQ EIFSTLVNNKILLAAVGATVNEKQKKFVSFTDPISI QTYSFVISRPRPYYEVHNKPTDTGLGKVNNCFWYIYGALLQQ GLYLPYADSGRIIIGTWWLVVLVIVTTYCGNLVAFLTF PKIDIPVNRVMQLLRNDRGMTWSIRRGTFLEEMLMVQVISSPI IYDSTEPKYMQLYKGSQIIGELTDELVERIEAGQHVH IDWRNNLRYLMKRQFLRTDRCDFALSTDEFLDEQIALVMPK DSPYLELVNEEIKRMHQFGFIQRWVAQYLPAKDKCSGTG RVMDVQNHTVNSSDMAGSYWILLLGFVSGLFVFVCEFAVA WYRKHRAARAATVAYRD(SEQIDNO:12) CquiIR93a(Culex MAAVILDREYLDNQYEALLENTKRTFEQILRDNFKNGGLIVK quinquefasciatus) YFSWTSINLRRDFTAVLSVSNCENTWDVYRNAAKENLV IMAITDTDCPRLPSHNAIMIPKSIPASGIFEELPQVIMDMKTMK AFSWKSAILLYDDSFDRDIVARSVLALSKESEDVLP LSLSLFRIESHTHMWEKRKAVRKVLLGLPTRYIGTNFIAIVTA TTMELVMDIAKELKMVNPLAQWLYVISDTTAEQNNIS SVHSIISEGDNIAFVYNMRKTAASCESQTLCYIENLVNALVKG LSKLIREEKAVYGQIADEEWEVIRMTKVERKNDILQI IKEERVGKDTCNECSMWKVQSGETWGYTYQLPADDVLSGT AVGRRKQVEMLDVGYWTPQDGFVMADFLFPHISHGFRGIH LNFYTYHNPPWQFVSFNESGHPTLSGGVVMDILEELSRKLNF TYTVIVAQTNIEYVGNLTEDGNNTSIREIHTVTTDIPS EIMKSLIDNKILLAAVGATVSEKQKKFINFTVPISIQTYSFIVSR PKELSRVFLFLSPFTVDTWMCLGLTILMMAPLLYV VNRVSPFYEHHGKSNKLGLGKLNNCFWYLYGALLQQGGLY LPYADSGRIIIGTWWLVVLVIVTTYCGNLVAFLTFPKIAV PITTISQLVRNNEGITWSIRKGTFLEQFLRETDDAKYLKLSHG ATFISDESDSMVQSIRNGHHVHIDWRTNLKYLLKREF LKNDRCDFALSLDEFLDEQIALALPKASPYLDVINAEITKMH QFGFIHKWLSNYMPSEDKCSKARKNTDVENHTVNNDDM AGSYYVLLIGFSSGMFLFLIEFGWRFYKKSKEQSLQPFTD (SEQIDNO:13) ApisIR93a MTGYNTDCPRLPTDEAITIPLTVHHSELSQMILDLRMSNAFS (Acyrthosiphon WKSAVLMHDNSIGDSVLQHIVTSLTKYYPSNIMSPSIT pisum) IFEIYTQGSEWKRRKLFMEDLQHFLKMSEINSNYICIVSILYVP LILDVAKSLNLMTAENSWLIIIPDIDSSRNNTSSFT NLLSEGENISFIYNSTKTGSKCIGGILCLVDELMSVFIMAFSALI QQEIELSQRVSEEEWDEIRPSKIDRRQSMVSFIKF RLNESGVCETCPLWQIDSGVTWGQEHFGQGCYILPVGNWNT KTGLKLTEPLFLHLANGFRGIALPIATFNFPPWQIVNFN RSGHLIGYSGLVFDIINQLAKTLNFTYNVIVISNTEQMNTTRT LFMQNNVLGEHDAVVSKPLWDKMIDLVRSEKVFIAAA AFAVKEANQILVNYTTHISLEPHQILVARPKELSRALLFTAPF TLLTWLCIAIVVGLMGPLLNVFHVLSPYYEYHNIPRK GGLNSPLNCFWYVYGALLQQGGAHLPDADSGRLVVGTWW LFVLVIVTTYSGNLVAYLTFPQMDSMVSNVADLMARKPQGY SWGIPKTSNLHSLLTVNDTMVKELIKNAEHHEELSRSIIERVR SGKHAFIHRRTNLMYIMKNDFLKTNRCDFAIGNEDFA EEKLAMMLSKESPYLSRINREIEKMHKVGLINKWLVDTLPKK DQCWTNTQLEVTNHKVNLDDMQGSFIVLLLGVLSSLVS FVFEYILHKYINRRQIVITPFIN(SEQIDNO:14) BmorIR93a MKIWVLGVLCLAISVQGEDFPSLITANASIAVILDRQYLGDKY (Bombyxmori) QTVLDELKDYIKELARVELKHGGVLVHYYSWTNISLN KGFLAVFSIASCEDTWELFSRTEEEDLLLFALTEVDCPRLPQR SAITVTYSEPGEELPQLLLDLRSSNAISWKSAVILHD DTLGRDMVSRVVQSLTSQIDEESARPVSVTVFKMKHEMNEY LRRKEMHRVLSKLPVKYIGENFIAIVTSDVMTTMAEIAR ELLMSHTMAQWLYVISDTNAHASNLSGFINTLNEGENVAFIY NITENGPDCKNGLMCYSQEMMSAFISALDAAIQAEFDV AAQVSDEEWEAIRPSKVQRRDILLKHMQQYILAKSVCGNCT LWRALAADTWGVTYRQNDVPEQINEHANGSTGVIEHLEL MNVGIWRPIDAMTFADLLFPHVHHGFRGKELPIITYHNPPWT FLQANESGAIVKYSGLMFDIVNQLAKNKNFTPRELSRA LLFLLPFTTDTWLCLGFAVILMGPMLYIVHRLSPYYEAMEITR EGGLATIHNCLWYIYGALLQQGGMYLPRADSGRLVIG TWWLVVLVIVTTYSGNLVAFLTFPKLEAPVTTISELLKNSDA YTWSVTKGSYLEMELKNSEEPKYKRLIKEAELLKETGG IEGTIHAARGTLDRVRGQRHLIFDWRLRLTYLMSADHIATET CDFALAVEDFMEEQVAMIVPAGSPYLPVINKEINRMHK AGLISKWLSAYLPKPNRCLKISTVTQEVSNHTVNLSDMQGSF FVLFLGNDKIYVYMYIAELI(SEQIDNO:15) TcasIR93a MLLELVLSSAFVCVIRAVIIDREFLSNEYEVIKHAIESYLVFAK (Tribolium REILKHGGVNVQYYSWTTINIKKDVTAIFSIASCPD castenium) TWRLFRQARDANLLHMAISESDCPRLPPDEAITVPLITRGEEL PQLLLDLRTRQTYNWNSAFILYDDTLSRDQVTRVVKS ITAQYSNLRVNAAAISFVKLETRLPMDEIRRQVKEILSSVSIKT VGGNFLAIIGYELVELLMEYAKMFGLVNTRTQWLYI ISNTHFRHKDINRFRQLLSEGDNIAFLYNNTVNNDTCTGGIQC HCEEILSGFTRALDEAILFEWETSSQVSDEEWEAIRP SKLDRRNSLLQGIKTFLLQRGQCDNCTSWLMKTGDTWGREY QQNGTDSGGLISVGNWRPSDGPSMSDELFPHIVHGFRKR NLPIVTFHNPPWQIIRSNESGAVSEYAGVIFELIKELSKNLNFT YTVELAKIGQEFSANLTKNEAQVVTNFIPDSILDMI RNKSVAFGACAFTVTEESKRLINFTSPISTQTYTFLVSRPRELS RALLFMSPFTGDTWLCLSASIVSMGPILYYIHKYSP VYEYKGLSKRGLSSVQNCIWYMYGALLQQGGMHLPQADSA RIIVGAWWLVVLVLATTYCGNLVAFLTFPKIDIPITTIDE LLAHSGTVTWSMPKGSYLERTLKYTTEPRFRYLFDKKVEVG NFKNMIEDIENGKHVHIDWKIKLQYIMKQQYLDSDRCDL ALGLDEFLNEQLAMVVSQDTPYLEIINDEIKKLHQVGLIQKW LTDYLPKKDRCWKNNRHIVEVNNHTVNMDDMQGSFFVL FLGFLLSFFITIGEKLWHKYVTKKKMKIIQPFTT(SEQIDNO: 16) PhumIR93a MLLFIFRIVFFLIIFCKKTGGNYFSDSHNVTLAVIVEQKFASKD (Pediculus DLSFVIKNLISDARKKFVKNGDLTVQYHTNTNTIPK humanus) KNLIAVLSIASCENTWKIFRNAEDDSILHLAITEADCPRLPFEE AITVPLIREGGEISQIILDIRTIHGIDWKSAVIFYD TSAIDGEEIQGITSALSMSVPIHSVDPASVSIFKLERKKNEWSR RKQIRNILTNFPSKILGSNFLVIAKRDLVGVIMEVA KSTGLVHPLSQWLYIIPDTNVIRDNITALSTLLMEGDNVSFIY NGTSDNPDCIVRLICHVDELIKSFTVSLNELIREEIE LSSQVSDEEWETIKPTKLDRRISLLSHIKTKLSESGGCDKCVT WLLKAGETWGKEFEIRKKGESRYDDFLQDVGLWHPRS GHVMKDILFPHIVHGFRGRSLPLISFNHPPWQIINHNESGQFV EFKGLVFEIVNELAKSLNFSYSVIYPQQKDKQNFFND SAKYEGLNGTQDFSTIAANWEIIIEAIKNKKVFLGAVAFIVSPE HKRFINFTTPIGIEPYTFLVARPQELSRALLFLSPF GGDTWLCIALAVAIVGPLLNWFHRSTPYYDYFNTRTSGGLQ TVTNCLWYMYGALLQQGGIHLPMADSGRIIVGAWWLFVL VIVTTYSGNLVAFLTFPKMDVPINTIQELLLRKNSLNWGFVR GSPVDLRLKNNVDPKYKELYDNAQLYRKLESETIEKIR KGEHVYMDWKTNMLFLTKKQYVETGTCDFTFGTEEFLEEQL AMVIAQGNPYLPRIDQEIRRIHRVGLIYKWLQDYLPKKD KCWSTNRLTEVTSHTVNMRDMQGSFFVLFLGIILSTILILTEY FYKKKTDREKNVIKPFTT(SEQIDNO:17) IscaIR93a MNNKNMMTFHREFVSVVTQPIDDDFQKLVVGFPDGANVLA (Ixodes AYPEIADNDCPVEPGCQLPLAMETVAKTIGDKLEKGTYRT scapularis) TEFFTTKFIFSNTSKSLLLASGKCGQCARFIIRSVAKVQGIQEF LKIGEWTPAVGLKMTHKQFFPGIMGNLGGIRLTIGV INDPPMSVVEMSPDRKTVKNVTGTMADMVEALAKGLNFTY TWKVPKEEIPGSKENGNWNGLIGMLATGEADLGAYGFSVT KERSEVVNFTSAYDESPYKILVPKPRANYKYLFLDPFTWDTW VAVLVSLVLIGPILWGIHCASPFYDYHGLRDNKGLFLL QNCEWYCFGAIIQQGGIHLPEAISGRILVGFWWLFVIVTLTTY SGNLVADLTFPKIRNPVDSVENLVAHRGYMRWGAFKG QAVFELLKSQEQGPLKVLSDRMNVFEPNHEMWVLDQVRLG YMALIGSEVNMFHYLGRELNRTGECDFAVARGEVIRDVKS LAVAPNFAFLERLNNEPDHDGRPPPRRLKRLVESGLVMRWK KKYWPQDNECTVESKPQAGDIRKITLRHMTGSFWVLGVG FFSSFAALFVEFVRRKRELTAPPTHKPPTVIHTKSPFFTRTEYS GKDTLTTDRFATDYGGRGPRDNAGFAFSPPNSPFRY NGYPNNRSDLIPYNYPARR(SEQIDNO:18) HmelIr93a MKLWMVACVIWSSLQYGQAEDFPSLITANASIAVVLDRQFL (Heliconius GDEYQTTLDEIKDYIKELARVELKHGGVNVHYFSWTAIS melpomene) LKKGYLAVFSVASCEGTWSLFQKTEEEQLLLFALTEVDCPRL PTDSAITVTYAAVGQELPQLFLDLRTQKGMNWKSAIIL HDDTLNLCYIFLLLRRLIHKKQENLESLSFYLLNHDDDVPSIS VTVFKMKHEVNEYLRRKEVNRVLSKLPVKYIGEKFIA IVTTAVMATIAEAARELLMSHTQAQWLYVISDTSGRGNFSNL INDLYEGENVAYIYNVTENDEGCKNGLICYAKEMMSAF ISELDSAVQEEFDVAAQQYIMVKSECGNCSWWRALAADTW GATYREKTYETKRNVTSIVIEHVELLNTWLCLGFAVILMG PTLYIIHRLSPYYDAMEITREGGLSTIHNCLWYIYGALLQQGG MYLPRADSGRLVVGTWWIVVLVVVTTYSGNLVAFLTF PKLEIPVTTISELLESKTYTWSISKGSFLEMQLKSSDEPKYKAL VKGAEVTGGINVVEGSLVSGSEILNRVRNQRHALID WRLRLSYLMRAETVKTDTCDFALSAEEFMDEQIAMIVPAGSP LNRMHKAGLITKWLSAYLPKRDRCWKTSTVEEVNNHTV NLSDMQGSFFVLFLEK(SEQIDNO:19) Msexlr93a MRLKLVGFLCLVCRVSGEEFPSLITANASIAVVLDRQYLGDK (Manduca YQAVLDELKDYIKELARVDLTHGGVVVHYYSWTSISLN sexta) KGFLAVFSVASCLDTWDLFSRTEEEELLLFALTEVDCPRLPLR SAITVTYAEAGEELPQLLLDLRTSNAFKWKSAVILHD DTLNRDMVSRVVQSLTSQIDDESASPVSVSVFKMKHEINEYL RKKEMHRVLSKLPVKTVGENFIAIVTSDVMTTMADTAR ELLMSHTMAQWLYVISDTNIHNSNLSGLIRALYEGENVAFIY NQTDNSPDCKNGIMCYCQEIMNAFISALDAAIQDEFDV AAQVSDEEWEAIRPNKIQRRDMLLKHMQQHISTKSRCGNCT TWRALAADTWGATYRHFTEDDILKENDNGTEATGVIEKV TLLDVGFWRPIDAMTFFDVLFPHVQHGFRGKELPVITYHNPP WTILHTNESGAIVKYGGLMFDIVNQLAKNKNFTIKILL PGNVKNEISNETDALHSRRAMLALAAIAKGQAALAAASFTIL PNPTPGINYTIPVSTQPYAFLVARPRALSRAMLFFLPF TADTWLCLGLAVITMGPVLYIIHRMSPYYEAMKITRQGGLAT IHNCLWYIYGALLQQGGMYLPRADSGRLVVGTWWLVVL VVVTTYSGNLVAFLTFPKLEIPVTSIAELIENRALYTWSINKGS YLEMELKNSEEPKYKALLKGAELTKPTHSSETNAHA GVEDFMDERVAMIVPAGSPYLALLNKEINRMHKAGLITKWL SAYLPKRDRCYSMSSMAAEVNNHTVNLNDMQGSFFVLLL GDFFFIVLNDETSLPFV(SEQIDNO:20) Mdeslr93a MMLRAHSCLTLCAVLVVSINQSEANDFPSLLVANATMGVIID (Mayetiola HGYLGDRYESTLDTMKQIIERVIREDLRGAGLFVKYFS destructor) WSRINFNKDLTVIFSIASCKSTWETFFHARRERLLLLAITDPDC PRLPSHEALTIPRIKVGMELPQIILDIRTSKSVNWK TVAILYDDIFDRDTISRVATALTVESSSMAMSISLLKLNSSTDS FERRENIKRSLLSFPNRFIGKNYLVVATIPTTILEI ATEMNMIDSKSQWLFLVSNPKKTNISTLLPFIKEGGNVAIATN NTANDDNNCAKTDECLYHELIKYVALSLSKLLREEEA IYGQISDEEWEAIRLTKRERRDSMLEYIQDKLKNSPICTPCVK WKFEAAETWGLRFNNIQGFA(SEQIDNO:21) AcepIr93a MWSLHDAARKEELVHLAITDEDCPRLPDSEGVSIPLILPGKEL (Atta SQIFFDMRSIDALLWNNVNILHDDTFDRDTIGRVTKA cephalotes) LSTSLPNKKFNLVSRTLFTFKHANSERNRRYDIKNMLESFHV EQLGKCFLVIVTIDTAADVMEVAKSLNMALPDSQWLYI ITDSVVRNSTNITSFADLLTEGSNVAFIYNVTDSDTYCNELVS ALANALKMSLMTEIELYSHMTDEEFELIRLNKQERRQ EILKSIKIQLIEDTFSTNGVCGKCLFWRFASAITWGNFFIHGKN VAHLIESGTWIPVLGANFTDVLFPHVMHGFRGINVP IATYHNPPWQTISLTNSGEKEYGGLLFDVVRYLGKKLNFTYN VLSPAINRTKFTRNATVANVVLTSTTREMPSQIIDMIL EKKVLFAACAYTVNDHGRKQINFTLPIFMQTYSFLTAKPGQL SRALLFTAPFTKETWACLAASIIIMGPVLYLIHKYSPS STKTSGLNSCWQCVWYIYGALLQQGGMYLPHSDSARLLVG VWWLVVMVLVATYSGSLVAFLTFPNTDTAILTVDDLIAHK NKLTWGFPNGSFLEEYLKNVEEEKYHILLERAIIHNATQEAD MVEQIKMGKHVLIDWRSTLRLHRMHESGLMNKWIAEQI PVKDKCSDSFANQVVEERKVNVTDMQGIFFVLFMGNVFFAIP SFGECNNISWE(SEQIDNO:22) AechIr93a MNMISFFFLAWILNSGDAFSDFPSLMSTNASMAVVIDKSFFD (Acromynnex NKAEYRDTVKNIYNFITAITRKEIHMADIDVHIFEGTK echinatior) VHNLRDFTVLLSVTSCYQMWSLHDAARKEDLVHLAITDQDC PRLPDSEGVSIPLILPGKELSQIFFDMRSIDALLWNNVN ILHDDTFDRDTIGRVTKALSISLPNKKFNLVSRALFAFKHANS ERNRRYYIKNMLESFHVEQLGKCFLVIVTIDTAADVM EVAKSLNMALPDSQWLYIITDSVVRNSTNITSFIDLLTEGSNV AFIYNMTDSDTYCNVSLKCYIQELVSTLANALKMSLM TEIELYSHMTEEEFELIRLNKQERRQEILKSIKIQLIEDTFSTSG VCGKCLFWRFASAITWGNFFVRGKNVAHLIDSGTW IPVLGANFTDVLFPHVVHGFRGIRIPIATYHNPPWQTISLTNSG EKEYGGLLFDVVKYLGKKLNFTYNVLSPAINQTKFT RNATVANVVLTSTTREMPSQIIDMILEKKVLLAACAYTVNDY GKKQINFTLPIFIQTYSFLTSKPGQLSRALLFTAPFTK ETWACVAASIIIMGPILYLIHKYSPSSTKTSGLNSCWQCVWYI YGALLQQGGMYLPHSDSARLLVGVWWLVVMVLVATYS GSLVAFLTFPNTDIAILTVNDLIAHKNKLTWGFPNGSFLEEYL KNAEEEKYHILLERAIIHNATQEADMIEQIKMGKHVL IDWRSTLR(SEQIDNO:23) SinvIr93a CLNLAAVIIDKNFFDDKVEYRDVMKNIHGLIASITREEIHTIDI (Solenopsis DIQIIRGTKINFRDYTVLLSVTTCHQMWSLHDAARK invicta) EELIHLAITDEDCPRLPDTEGVSIPIILPGQELAQIFFDIRSTDAL LWNNVNIIHDDTFDRDTIGRVTKALSTALPNKKF NMVSRALFTFKYSDSATTRRYYIKDSLENFHVDQLGRCFLVI VTIDTASDVMEVTKTLNMALPDSQWLYIITDSVVRNST NITILTDLLSEGSNMAFIYNATDNDTYCNVSLKCHIQELVAAF VNALKISLMTEIELFSHLSDEEFELVRLNKAERRREI LKNIRIKLIDENFATGGVCGKCLFWRFASAITWGNFFLHSKN VAHLIESGTWIPGLGLNLTDEIFPHVVHGFRGISLPIA TYNVCKYVPFSLSTIKFVRFDFFFQNPPWQTISLNNAGEKEYG GLVFDVIKYLGKKLNFTYTVLTPASNRAVKFIRNETA DVVLASTTREMPPQIIDMVLEKKVLLAACAYTVNNFGRGKV NFTLPIFMQTYSFMTAKPGQLSRALLFTAPFAKETWACL ASSIIIMGPILYLIRKYSPDNTETSGLNSCWQCMWYVYGALLQ QVPMILGGMYLPHSDSARLLIAVWWLIVMVVVATYSG SLVAFLTFPNMDAAILTVDDLIAHKNRITWGFPNGSFLEEYLK NSEEEKYHILLERSIIHNETTASKVIEKVKAGKHALIDWRSTL (SEQIDNO:24) PbarIr93a MLQYDLSLDMISIFFLAWILNSGDAFGDFPSLVSANTSMAVVI (Pogonomyrmex DKSFFDNKAEYRDIVRNIYNYIATVTKEETNTIDIDV barbatus) HIFRGTRVNNLRDYTVLLSVATCHQMWSLHDAARKEELVHL AITDHDCPRLPDSEGVSIPLVSPGEELSQIIFDIREIDA FAWTNVNILHDDTFDRDTINRVTKAISRSLPNKKFNLISRALF AFKNADSERSRRYYIKHVLENYRVDQLGRCFLVIVTI DAAADVMEVAKSLNMALPDSQWLYIITDSVMRNSTNITSFV NLLTEGSNVAFIYNTTDSDTYCNVSLKCHIQELVGALIN ALKLSFMIEIELYSHMSDEEFELIKLIEDTFATGGVCGKCLFW RLASAITWGNFFVHGKNTAHLIDSGTWMPNLGANLTG PIFPHVVHGFRGISVPIATYHNPPWQTISLSDSGEKEYGGLVF DVVKYLGRKLNFTYSVISPASNRIVKFTRNATTDMIL TSTTREMPSQIIDMILEKKILLAACAYTVNGKGKGHINFTLPIF MQTYSFLTAKPSQLSRALLFTAPFAKETWACLAASI IIMGPILYLIHKYSPSNTRKSGLNSSWQCIWYVYGALLQQGG MYLPHSDSARLMVAVWWLVVMVLVATYSGSLVAFLTFP NMDITILTVEDLITHKDRLTWGFPNGSFLEEYLKNAEEEKYH TLLEKAIIHNATQEAEVIKKVKAGKHALIDWRSTLRIT ITMHCPSRFLMRNDMLTTDECAFALSTDEFMDEPIAMIISENS PYLNIINAELHRMHESGLMNKWTSEQIPLKDKCSESL TNQAVVERKVNVADMQGIFFVLFMAVSSAFAYRYDPWYRA DTQRPVDVITDVINELGVRILQQYSTRGNVAFSPTGVAFV LAALYEGSAGRGSQQIAQALGLPANRDVTRIGFRDIHRRLRS YLNADGFLGGLTLSRENTRLRPEYEDILRFYGFDLSSI EQEANVTVSTGDSSGTTKLPTSTVGVTTLPTETTNTGSVPDM TTTTTMMSTDVGTTLPPSGAETMIPSTVTDASTQQPLT MVPTGATDVPSTLAPVTGDGAAVQNASPTQSANSTTAVTSG ESVQSTTSAGAESVAGSPNTITPAVNADSQTTPTTVAGA GDQSPQTSPTVAADGVGTGEIVTSTIVPDATAADVTAAAATD AAGGMVSTSTQAQVSSTVATSTEAPMTTNTPSSAAMII ANTDSLAAAIDVNVTPANVTSPSEAILNTVTTNSLTTVAIANV ANVTIPSPVTETTADSVVSQPSTLADTPATTDIPGST ATNNLAMTTMTNIDGAAATTASLVDENTISMNRKKKDLTDV RINDNTVKQESTNESLNVRKRKARSPRGYFSSYPDEGIW MQDLEIWKSYNTVNPGDSSAGDSSAEISFLVNGCDVSSVSAS RYIAVLPFAYFPSLQAVALEFPLDDPRYNIILFMPTDK TDTHRLARDLSGKSLRLLRKRLQPTWVRATIPSFMLRGFVTL TSFLQREKETEIEEG(SEQIDNO:25) CfloIr93a MDMISVFFLVWILNSVDAFNDFPSLVSNNASMAIIIEKSFFDN (Camponotus KAEYRSVVSNIYNFISNITSDIEVHVFHDTKIDSFQD floridanus) YTVLLSVTTCDQTWNLYNAVRKDEIIHLAITEQDCPRLPEGV SIPLILPGKELSQIFFDIRMADALLWNNVNILHDDTFD RDTINRVTKAISIALPNKKFNLVSRSLFVFKHADSERNKRYYI KEMLESFHVDQLGKCFLVIVTIDTVADVMEAAKMLNM VQPDSQWLYVITDIVKNNSTNITSLIDLLSEGSNVAFIYNATD NNTYCNNNLICHIQELTMALNNALKISLMTEIELYNH VSNEEFEIVRLNKRERRREILKFIRTKLAQDNFATGGICGKCL FWRFASAITWGNFFIRDKSTAHLIDSGSWIPTLGMNL TDVIFPHVVHGFRGINLPIATYHNPPWQIISMTNSGEKEYGGL LFDVVKYLGNKLNFTYSVLSPVSNRTIKFTQNETQAD MTYSFLTAKPGQLSRALLFTAPFAKETWACLASSIIIMGPSLY LIHKYGPTSTKTSGLNSSWQCIWYVYGALLQQGGMYL PYSDSARLLIGIWWLIVMVVVATYSGSLVAFLTFPNMDSSILT IDALLANKNRLTWGFPNGSYLEEYLKNAEEEKYHIML KRAKIYNATQEAEVIEKVKAGKYALIDWRSTLRFLMRTDML TTGRCSFSLSTDEFMDEPIAMIINQDNPYIKIINAELHR MHESGLMNKWVTEQIPMKDKCSDILANQAVNERKVNVAD MQGIFFVLFMGVAGSIFLLCCEFYWHKRQVAKRRKLIQPFLS (SEQIDNO:26) LhumIr93a MNTRCLNAIVIDKSFFDNKIEYRDTVRNIVDFITNVTNEEAHM (Linepithema SDINMHIFRDTNVNNLRDYTVLLSVATCYQTWSLHDV humile) ARKEELVHLAITNQDCPRFSDSEGVIIPLIPMGDELSQIFFDIRT ADALFWNSVNILHDDTFDKNTISRVTKAISTALPN KKFNLVSRSLFVFKHANSDRSRRYYIKDMLETFHVEQLGKCF LIIVTIDAAADVMEVAKTLDMVQPDSQWLYIITDSVIR NSTNITTFIDLLTEGSNVAFIYNATDSDAYCNVTLMCHVQELI AALSNALKLSLMTEMELYNRMSEEEFELIRLNKNERR QEILKNIKIKLVEDTFATGGTCGKCLFWRFASAITWGNFFIHG KTSAHLINSGTWIPTLGVNLTDAIFPHIVHGFRGINL PIATYHNPPWQTISLTNTGEKEYGGLVFDVIRYLGKKLNFTY TVHSPRSNRTVKFIRNESDIEVVLTSTTRKIPPEIVDM VAEKKVLLAACAYTVNDRGRGKINFTLPIFMQTYSFLTAKPG QLSRALLFTAPFTKETWACLAASIIIMGPILYLIHKYS PSSTRTSGLNSPWQCIWYVYGALLQQEKCDEKMFLGGMYLP HSDSARLLVGVWWLVVMVLVATYSGSLVAFLTFPNMDTA ILTVDDLIAHKSQLTWGFPNGSFLEEYLKNAEEEKYHILLERS IIHNTTQEAEVIKKVKAGKHVLIDWRSTLIRLISTSD KNDDNDILLEQVCDEKRSVIN(SEQIDNO:27) HsalIr93a MISVLFLAWILNFGNAFNEFPSLMSANASMAVVIDKSFFDKK (Harpegnathos HEYIDVTKRIHEYITNIAREEMHMGDINVRVFRNAKIN saltator) NLREQDCPRFPDTDGVSIPLVVAGQELSQIFYDLRSYDVLNW NNINILHDDTFDRDTISRVTKAVSTPLPNKKFNMVSRS LFAFKHANSERSKKYYIKEILEKFHVDQLGKCFLVIVTTDVAF DVMEVPDSQWLYVIADSMVRNATNITSFTEYLSEGAN VAFAYNSTDNDTYCDAKLLCRVQELIGSLANALKLSLMIEIE LYNRVSEEEFEFIRLNKRERRREILKNIQIKLTDDTFA SGGGCGKCLFWRFASAITWGNFFLRGKNIAHLIDSGMWIPSL GANLTDVIFPHISHGFRGISLPVATYHNPPWQSISLTN SGEKEYGGLIFDVIKYLGKKLNFTYTVLSPTSNRTVKFTQNET QADVTYSFLTAKPNQLSRALLFTAPFAKETWACLAAS IIIMGPILYLIHKYSPGTKTSGLNSSWQCVWYVYGALLQQGG MYLPRCDSARLLVGVWWLVVMVLVATYSGSLVAFLTFP NMDVAILTVDDLIAHKGRVTWGFPNGSFLEEYLKNAEEEKY HIMWERSEIYNSTQEVEVIEKVKTGKHVLIDWRSTLRFL MRNDLLSTGGCSFSLSTDEFMDEPIAMIISQDSPYTKIINAELH RMHESGLMTKWITEQIPMKDKCSDSSGKQGVDERKV NVLDMQGIFFVLFMGVVGSIFLLCCEFYWHRRQITRRSKLIQP FLS(SEQIDNO:28) AdarIr93a MSPEEGKNGQKINQTCQPVEESTYAPDSNEMNSSNDAEKDH EMQSNIQYVMDILPHLDPYYVRRIIEHFDSVEKALAILL EGNEDAQSKDSRKDINGEIVPEDPLDSFYLQTGIDRLNIFDGD EFDVMSKSHVKGTIKKGKGMPGNPKSFKALLDDKSHV NEMRHVYRQYSTLADMDDDEYDDTFEAMAESESRHIKFAK GTRISGIEESDDDDESDTEDSDPEAEPHKMAGFEFCENPE ITRKRYEERLISKGVKPQAPKETADVRGNPKASNDANNDKVI KTRDLYRSGHLPDETCVKKLCPSNGTDVTLLILVTSAP THREQRLAIRQSWGYYGSRRDISIGFIVGQTDESRIEDQLAAE SYMYSDLIRGNFIDSYKNLTLKTISLLEWTKLHCSNA SFLLKTDDDMFINVPKLLQFMEVHNNQRRTIFGRLAKKWKPI RNKKSKYYVRPAYLLTADIISELFEKSLSQTYLKLEDV YTTGIVAQLLNIRRTNVKEFLNRRIAFNQCSIKKAISIHMVKN NEQLDLWKKLIDVNILCYIESFLVHFIRSLSKLIREE QVVFGQISDEEWEIIRPSKVERKKKMLQMIQNPPWQFVSYNE SGSPVITGGVIYDVLSELSRKLNFTYTLVITQGASEQN GSLIDDNSTVSDGNSMVISRLRFFMKCFCLLQTLYETNGLTSD IPQEIYSTLVNNKILLAAIGTTVTEKRKKYISFTDPI SIQTYSFIDIPVNRIMQLLRNERGMTWSIRKGTFLEEVLMVRQ HYRQQLQLHLANRMSFPSPVWTQESDENKYIELYRGS QVITELTDDLVRRIEAGQHVHIDWRNNLKYLIKKQFLATDRC DFALSTDEFLDEQIALVMPKDSPYLELVNDEIRRMHQF GFIQRWISQYLPSKDRCSGTSNKAMDVQNHTVNSSDMAGSY WILLLGFSSGLIIFIGEFAIHWYRQRRLAKAVVTSYSS(SEQID NO:29) AfloIr93a MISVLLLVWCINYGSSYNDFPSLITSNATMDPDCPRIPDTDGIT VPSIVPGEELSQIFLDLRMTDILSWNVINILHDDTF GDKATSSNDNVTILLSNANTSIFSLRHGNTGGGRKSSVKKTL NDFHVDQLGHCFLVIATVDMVADVMTVANSLNMVHPGS QWLYVITNSVSGNLINTTFINLLAEGGNVAFMYNATNLDGFY KIKLKCYIKNLIEALAKALEYSLTNEIELFKRMNEDEF EMIRLTKSKRRTELLKNVRNPPWQIISMSKTGKKLYEGLIFDA INYLSMKLNFTYTVIMPETSQISRSWNTSQFAKLGEK IKEMTMSTTKKVPLEIIDLVRQKKVLLAACALTVNECGNTTF NYTVPIFVQTYSFLTAKPSQLSRVLLFASPFTKETWAC LAVSIIIMGPILYLIHKYSPYSTKASGLNSSWQCVWYVYGALL QQGGMYLPHNDSARILIGIWWLVVMVLVATYSGSLVA FLTFPRMDTSILSVEDLIAHKDRISWGFPNGSFLEMYLQNAEE PKYHVLLSRAERHNDTEEERLVGRVKEGKHALIDWRS SLRFLMRKDFLLTGSCHFSLSMDEFLDEPIAMIIPYGSPYLPVI NAELHRMLESGLMNKWITERMPMKDKCWEAPGSNQA VNKRKVNVADMQGIFFVLFIVSSVFVHGYDNVGFDGWYQP QYTAHGNVAFSPTGVGFVLAALYEGSAGRGRQQIVDALGL PRDRDITRIGFRDIHRRLRTYLNADGFLGGLTLNHENTRLRPE YEDILRFYGFDLSIPEEEMNETTFAPETTSSVAIEQS TTETKTVIPDEITTQSITTQGIQSFETITNSGTPISTTSSVELTGIV TSSTIEQDKLTQTTPAASVLTNNPNAAMTTVSS SIVVTSSSTETTTTSSIPTIINPNLITTSSSEIVTTTPSVTSTPPS TIPSTTPIIIITTVASTISEEPQTTIANLTQPIT TVTLSNQSPSIEESTSTLSTSTSTSTTPFTTTTTTSTTTSTTSIPSS TSETPLPPTTLIIVETPESTTISTGQTTKESVV MTESIPESTIMPPTMSAPINAGATVTEVSTTLPVNITEISTNSTI PTTIQTNEMSINETSRFTNKPDDENTISVDSLNNQ SSISNEMESTELPVTIVAGEIGSTIGQKTITTTVSSNTMMNRRK RSDRSPRGFFSSYPDEGIWMQDLGIWKPYSTSLNEA SVRDSTEISFLVNGCDVSSVTASRYFAVLPFAYFPSLHAVALE FPLDDPRYNIILMMATDRRDTYRLARDLGGKSLRLLR KQLQATWVRATIPSFMLRGFVTLTSFLQRLGILDVFEPRTADL SPMTPDLGVYARDVQQSIGVNIRNYMKPDRTHSRNGL FERAGPVPFTVVHPFLYFIVDAETSVVLIAGRVNDPLNSRIL (SEQIDNO:30) BimpIr93a MISVLLLLWCVNYGDSYNNFPSLITTNATMAVIIDKSFFDNN GEHRNVMGVVHDLIINTVKKEMHIGGIVVRIFRDADVN LWQGYTILLSVASCCITWRLHEVARKEELIHLAITDPDCPRIPE TDGMSMPVVVPGEELSQIFLDLRMMNILPWNVINIL HDDTFGRDTISRVMTAISDKLPNKQVNLISRSIFTLKHETTRSE RKSSVKKTLNDFHVEQLGHCFLVIATVDMIADVMGV ARSLKMVHPGSQWLYVITDSATKNMTNMTAFVDLLAEGGN VAFMYNATNLSNYCEIKLICYVEKLIQALAKALEYSLTNE IDLFKSMEEEKFEMIRLTKRERRAELLKNIRIHLSQNAFASEGF CGRCLLWRFSSSITWGNFFSRGRNMAHLLDIGTWSP GFGVNLTDVIFPHIAHGFRGTNLPIATYHNPPWQIISVSKTGQ KLYEGLVFDAINYLGSKLNFSYTAITPEVTRNSNFTV NENKKDAINFTVPIFVQTYSFLTSRPKQLSRALLFASPFTKET WACLAVSIIVMGPILYLVHKYSPYSIKTSGLKSSFQC VWYVYGALLQQGGMYLPHCDSARILIGVWWLIVMVVVATY SGSLVAFLTFPRMDASILTVDDLLARKDGITWSFPNGSFL EMYLQETDEPKYHTLLSRAESHNDTEEEKLVERVKDGKHAL IDWRSSLRFLMRKDLLLTGVCHFSLSMDEFLDEPIAMII PHDSPYLPVINAELHRMLESGMMNKWITERMPIKDKCWEVP GSNQAVNKRKVNVTDMQGIFFVLFMGIILAFFFLFCECY CHRRKISKERKLIHPFVS(SEQIDNO:31) BterIr93a MISVLLLLWCVNYGDSYNNFPSLITTNATMAVIIDKSFFDNN GDHRNVMGVVHDLIINTVKKEMHIGGIVVRIFRDADVN LWQGYTILLSVASCCITWRLHEVARKEELIHLAITDPDCPRIPE TDGMSMPVVVPGEELSQIFLDLRMMNILPWNVINIL HDDTFDRDTISRVMTAISDKLPNKQVNLISRSIFTLKHETTRSE RKSSVKKTLNDFHVEQLGHCFLVIATVDMIADVMGV ARSLKMVHPGSQWLYVITDSASKNMTNMTAFVDLLAEGGN VAFMYNATNLSNYCEIKLICYVEELIQALAKALEYSLTSE IDLFKSMEEEKFEMIRLTKRERRAELLKNIRIHLSQNAFASEGF CGRCLLWRFSSSITWGNFFSRGRNMAHLLDIGTWSP GFGVNLTDVIFPHIAHGFRGTNLPIATYHNPPWQIISVSKTGQ KLYEGLVFDAINYLGSKLNFSYTAITPEVTRNSNFTV NENKKDAINFTVPIFVQTYSFLTSRPKQLSRALLFASPFTKET WACLAVSIIVMGPILYLVHKYSPYSIKTSGLKSSFQC VWYVYGALLQQGGMYLPHCDSARILIGVWWLIVMVVVATY SGSLVAFLTFPRMDASILTVDDLLARKDGITWSFPNGSFL EMYMQETDEPKYHTLLSRAESHNDTEEEKLVERVKDGKHAL IDWRSSLRFLMRKDLLLTGVCHFSLSMDEFLDEPIAMII PHDSPYLPVINAELHRMLESGMMNKWITERMPIKDKCWEVP GSNQAVNKRKVNVTDMQGIFFVLFMGIILAFFFLFCECY CHRRKISKERKLIHPFVS(SEQIDNO:32) DanaIr93a MKDYLKANSKCASCARWQIETAITWGKSQENRKFRAAPTRD AKNQNFEFINIGYWSPLLGFVCQELTFPHIDHHFRNITM DVVTVHNPPWQILTKDSHGVILEHKGIVMELLKELSRALNFS YYLHEASNWKDDYSITTSTSSNESDELAGSMTFRIPYR LVEMVQGNQFFMAAVAATVEDPDHKPFNYTLPISVQKYSFIT RQPDEVSRIYLFTAPFTTETWACLVGIILLTAPMLYAI NRLAPLQEMQIIGLSTVKSCFWYIFGALLQQGGMYLPRADSG RLVVGFWWIVVIVLVTTYCGNLVAFLTFPKFQPGVDYL SQLPRHKEISQYGLRNGTFFERYVQTTTRDDFKHYMARAQIY GNSQEENIEAVKQGHRINIDWRINLQLIVQQHFERDKE CRFALGKESFVDEQIAMIVPSHSVPYLHLINSHIDRLFRMGFM ERWHQMNLPSADKCTGKSSLRQVTNHKVNMDDMQGCF LVLLLGFMVAFAIGCGEFWYHHLYVHKTSRQPPSSVFTT (SEQIDNO:33) DereIr93a MRQQFLVISAFHEDIIEIAETLNMFHVGNQWMIFVLDMVGRD FDAGTATINLDEGANIAFALNETDPNCQDSLNCTISEI SLALVTSISKITVEEESIYGEISDEEWEAIRFTKQEKQAEILEY MKESLKTNAKCSSCARWRVETAITWGKSQENRKFRS IPSRDAKNRNFEFINIGYWTPLLGFVCQELAFPHIEHHFRNITM DILTVHNPPWQILTKNSHGVIVEHKGIVMEIVKELS RALNFSYYLHEASSWKEEYSVSTSAGSNESDELVGSMTFRIP YRVVEMVQGNQFFIAAVAATVEDFDQKPFNYTVPISVQ KYSFITRKPDEVSRIYLFTAPFTMETWFCLMGIILLTAPTLYAI NRLAPLKEMRIVGLSTVKSCFWYIFGALLQQGGMYL PTADSGRLVVGFWWIVVIVLVTTYCGNLVAFLTFPKFQPGVD YLNQLEHHKDIVQYGLRNGTFFERYVQSSTREDFKRYL ERARIYGSAQEEDIEAVKRGERINIDWRINLQLIVQRHFERDK ECRFALGKESFVDEQIAMIVPAQSAYLHLVNRHINSM FRMGFIERWHQMNLPSAGKCNGKSAQRQVTNHKVNMDDM QGCFLVLLLGFTVALLIVCGEFWYRRFRASRKQRQFTN(SEQ IDNO:34) DgriIr93a MRGQQKRISLRKALIQFAPTKHELRRQQFLVLSRFHEDIIEIAE TLSMFHVNNQWMFFVLEDPHNEFDANTVTINLDEGA NIAFALNETNFNCVDTLNCTITEVSMALVTSLSRMILEEQSIY GEISDEEWESIRFTKQEKQDEMLEYMKDYLKTNSKCA SCARWRFETAITWGKSQENRKFRAAPTRDAKNRNFDFINIGY WSPLLGFVCHELIFPHIEHHFRNITMDIVTEHNPPWQI LTKDSRGVIVEHNGIVMEILKELSRALNFSYYLHDATAQDYD NQLGPSTNESDELMGSMTFRIPYRVVEMVQGNEFFMAA VAATIDEQHKKRFNYTQPISVQKYTFILRQPDEVSRIYLFTAPF TIETWACLAGILMVTAPMLYIVNRLVPLQELQIRGL STVKNCFWYIYGALLQQGGMYLPRADSGRLVVGFWWIVVI VLVTTYCGNLVAFLTFPKFQPGIDYLNQLFGHTEIKQYGL RNGTFFEKYVETTTRPEFKRFIERATIYSSVQSENIAAVKHGD RINIDWRINLQLIVQQHFDKDKECRFALGKEDFVDEQ IGLIVPTSSAYLHLINQHLDKLFRMGFIERWHKTNLPSMDKC NGRNVQRQIANHKVNMDDMQGCFMVLLFGIILALFISC IEFWYYRFFVVGRDRKSIAFAN(SEQIDNO:35) DmojIr93a MKEYLKANSKCASCARWRIETAITWGKSQENRKFRTTPTRD AKNRNFEFINIGYWTPLLGFMCHELTFPHIDHHFRNITM DIVTVHNPPWQILTKDSRGVIVEHSGIVMEILKELSRALNFSY YLHEGHSSDTDDTIRQNMNDSDELMGSMTYRIPYRVV ELMQSNAYFMGAVAATIDEPSKKHFNYTQPISIQKYTFILRQP DEVSRIYLFTAPFTLETWGCLAGILLFTAPILYFVNR LMPLPELRIHGLSTVKNCFWYIYGALLQQGGMYLPRADSGR LVVGFWWLVVIVLVTTYCGNLVAFLTFPKFQPGVDYLHQ LFAHKEIKQYGLRNGTFFEKYVEATTREDFKRFIARSSIYNSV QSENIDAVKHGDRINIDWRINLQLIVQQHFELDKECR FALGKEDFVDEQIGLMVPTGSAYLHLINHHIDRLFRMGFIDR WHKTNLPSMDKCNGKNMQRQIANHKVNMDDMQGCFMVL LFGVILATIVSCFEFWYHRFFVVSRERKRVPFSN(SEQIDNO: 36) DperIr93a MNMFHVGNQWMFFVFETMRQDFDASTVTINLAEGANIAFA LNETNTDCMDTLNCTISEISMALVTAISKMTVDEQSIYGE ISDEEWESIRFTKQEKQYEILMYMKEYLKTNSKCASCAKWRF ETAITWGKSQQNRQFRTAPTRDARNQNFEFVDIGYWSP LLGFVCQELTFPHIAQHFRNITMDIVTMHNPPWQILTKNSHG VIVEHKGITLEILKELSRALNFSYYLHEAKTYDDEFPL NQSTNESDELLGSMTYGIPYRVVEMVQGNQFFMAAVAATVE DPDKKAFNYTQPVSVQKYSFITRQPDEVSRIYLFTAPFT TETWGCLVGIIFLTAPMLYAINRLAPLQELQIHGLSSVKSCFW YIFGALLQQGGMYLPRADSGRLVVGFWWIVVIVLVTT YCGNLVAFLTFPKFQPGVDYLNQLHRHTEISQYGLRNGTFFE KYVQRTTRDDFKQYVAKAIIYNNGQGEDIEAVKDGQRI NIDWRINLQLVVQQHFERDKECRFALGKESFVDEQIALIVPSQ SAYLHLINQHIDRMFRMGFIERWHRTNLPSADKCNGK SILRQITNHKVNMDDMQGCFLVLLLGFILAVFVGCIEYWFYR LYVQSDSRKPTVFTN(SEQIDNO:37) DpleIr93a METVVLDHQFLGDEYQMMLEDLEDYIKELVRVELKHGGINV HYYSWTSINLKKGFLAIFSIASCEDTWSLFLRAEEEDLL HIAVTEVDCPRLPSDSAITVTFADPGQELPQLVLDLRTRKAFN WKSAIILHDETLNRDMVSRVVESLTSQIDDISSISVS VYKMRHENNEYLRRKEVYRVLKKLPVKYIGENFIAIVTTDV MATIAEIARELRMSHTQAQWLYLVPDTDSHTGNVTNLIN DLYEGENIAYIFNFTDDRGCKNGLKCYAHEVLDSFISALEAA VLDELEAALQVSDEEWEAVRPTKLQRRNSLLWHMQQYL STRSVCGNCSSWRALSADTWGATYDRADENTSSLIEQVHLV QVGFWRPIDGVTFEDVLFPHIQHGFRGKQLPIMTYHSPP WTIVTYNASGAVTSYGGLLFDIVNQLAKNKNFTYAIYILLLA ENLRLNYTNETTTDTLYNTNRQLILSAIAKGHAALVAA PFTVSPDTHPGVNFTVPVSTQSYSFIIARPRELNRALLFLLPFT TDTWLCIAFAVVLMGPTLYVVHRVSPYYEAMEITRE GGLSTIYNCLWYIYGALLQQGGMYLPRADSGRLVVGTWWL VVLVVVTTYSGNLVVFLTFPKLEIPVTTVSELLDSGTYSW SIRSGSFLESQLKNSNEPKYEALLKRAELTSPSDGAENDAIVE RVRFSHHALFDWKLRLRYLMRADTEQTDSCDFALSTE EFMDEQVAMILPAGSPYLPVINKEINRMKKAGLITKWLSAYL PKRDRCWKTSAITQEVNNHTVNLSDMQGSFLVLFLAIV ERVRFSHHALFDWKLRLRYLMRADTEQTDSCDFALSTEEFM DEQVAMILPAGSPYLPVINKEINRMKKAGLITKWLSAYL PKRDRCWKTSAITQEVNNHTVNLSDMQGSFLVLFLDSQKTC APEKAVVELTPGTVWSTRY(SEQIDNO:38) DpseIr93a MRSSGCLLLLFGFQLYFLSWPMAVEGNDFSSFLSANASLAVV VDHEYMTRHGQNIMAHFEKILSDIIRENLKNGGINVRY FRWNAVRLKKDFLAAITVTDCANTWNFYRSTQETSVLLIAIT DSDCPRLPLNKALMAPMVEHGDELPQIILDAKVQQILN WKTAVVLVDQNILDNNSELVKAIVHESTTNHIAPISLILYKID DSLRGQKKRAALRHALSHFSPINHEQKNQQFLVLSKF HDDIIEIGETMNMFHVGNQWMFFVFETMRQDFDASTVTINL AEGANIAFALNETNTDCMDTLNCTISEISMALVTAISKM TVEEQSIYGEISDEEWESIRFTKQEKQYEILKYMKEYLKTNSK CASCAKWRFETAITWGKSQQNRQFRTAPTRDARNQNF EFVDIGYWSPLLGFVCQELTFPHIAQHFRNITMDIVTMHNPP WQILTKNSDGVIVEHKGITLEILKELSRALNFSYYLHE AKTYDDEFPLNQSTNESDELLGSMTYGIPYRVVEMVQGNRF FMAAVAATVEDPDKKAFNYTQPVSVQKYSFITRQPDEVS RIYLFTAPFTTETWGCLVGIIFLTAPMLYAINRLAPLQELQIHG LSSVKSCFWYIFGALLQQGGMYLPRADSGRLVVGFW WIVVIVLVTTYCGNLVAFLTFPKFQPGVDYLNQLHRHTEISQ YGLRNGTFFEKYVQRTTRDDFKQYVAKAIIYNNGQGED IEAVKDGQRINIDWRINLQLVVQQHFERDKECRFALGKESFV DEQIALIVPSESAYLHLINQHIDRMFRMGFIERWHRTN LPSADKCNGKSILRQITNHKVNMDDMQGCFLVLLLGFILAVF VGCIEYWFYRLYVQSDSRKPTVFTN(SEQIDNO:39) Dpul-1Ir93a MMQHLGANWSQWANIFNQVPAFSNLWEPIGHKWDNIFNQV PLSNHWELIGHKWDNIFNQVPFSNHWELIGHKTTFTRINP DTKFLDDEDVEGVHLVHDFDLVREMQVRLGKFAKGQAVFF PVMWSVSLSMKNVQSLASKPYVVGPKPSGPRFLLYIDSSG DIFLENMTQHIFRVDEDHAIKIETFEGKPITDTVLDGVITREKS DDDASCNGNIKEDGTTGKLKFVILDAIRCSGNDLTG LNILERIAFVREEIIIPMTPTEAELHVGGPKTKFEIKYDMIRLTD EMKMLDGCIIDCRYFDHQWIFIKQRHDRNHPNGSE AVKETTANANSSSERVNDLSCYTSNLLQVYVKALHQVIREEE THYFQTTEDDWNRSKPSAGDRRNNIFRTLQNMWKDATK WSSWLNWALKAVEIKETRKPTLLDVGVWDAAHGLVVYDDF FPHFTGGLRQRVISVTTMEFPPWQIFERNSQGKVVRHTGL VLELTKELGNLSMLWNHVEPADGKWGSRLSFSRWTGMVEQ VRTGSVAFAAAGCTVTADRMSAVNFSMSLDAQPYTFMFAR PKQLSRAYLFIQPYTPNAWITIFAMTIGAGSLIWSFNNITPFYD FYPDRPGSPIFSIWPYFYAKEKCLSL(SEQIDNO:40) Dpul-2Ir93a MLLRVLLVLASAFIHVQSAHYELYSELRPDERWFLDDTKLIP VSCENGDCSALFNKHNKHKIAKRAAVQVETMKDYIKFL LRGNKTKDDDTNTDPYRTANITLGVVMDKNLIGNLQTFTNIF DVANMPSNPEIDYLRLQKFNVTYLNPQDKLPSNINAVL SILPCDVLTRFDKNLASLPILHIAITSDNCPRITRWAVLMVPVV KTGAELPQIFTDLRLSDTLNWKEAVVIAEEHANKEL FDGLVDSLSRPVHKKDPLALTVVKLHGPVALRKKNFESQLL NLQVRPKGRNFILVSKQDTALWAFDAASHVGLVNPYSQW LFLITDSTDPAIFLPNVEDGQNISFLYNISDIETTANANSSSERV NDLPCYTSNLLQVYVKALHQLIREEETHYFQTTED DWIRSKPSAGDRRNNIFRTLQNMWKDATKCSSWLNWAMKA VEIKETRKPTLLDVGVWDAAHGLVVYDDFFPHFTGGLRQR VINVTTMEFPPWQIFERNSHGKVVRHTGLVLELTKELGNRLN FSVNVVEPADGKWGSRLSFSRWTGMVEQVRTGSVAFAA AGFTVTADRMSAVNFSMSLDAQPYTFMFARPKQLSRAYLFI QPYTPNAWITIFAMTIGAGPLIWAFNKITPFYDFYPDRP GSPIFSIWYNIWYCIGALLFQGQREMPIALSGRMVVGFFWLF VIVVLTAYSGNLVAFLTFPTYTNPINTLQDLIDNKGSL TWGILRGTALEDYLKTSDEKMYRELYEGAILHDTADDVLLD MIRNQQHVYIEWKTNLQWLMKQDFMKTNSCDFSLGTENF FLQQVALAFPRDSPILERVNLEIIYMQRGGLIEHWRQEFWPSA DRCSETATGGSDGDTIQAISVADMQGSFYVLFFGKTK NLGTLYNLFINGKFMYE(SEQIDNO:41) DsecIr93a MRQQFLVISAFHEDIIEIAETLNMFHVGNQWMIFVLDMVARD FDAGTVTINLDEGANIAFALNETEPNCQDSLNCTISEI SLALVDAISKITVEEESIYGEISDEEWEAIRFTKQEKQSEILGY MKEFLKTNAKCSSCARWRVETAITWGKSQENRKFRS TPQRDAKNRNFEFINIGYWTPVLGFVCQELAFPHIEHHFRNIT MDILTVHNPPWQILTKNSNGDIVEHKGIVMEIVKELS RALNFSYYLHEASSWKEEDSLSTSAGGNESDELVGSMTFRIP YRVVEMVQGNQFFIAAVAATLEDPDQKPFNYTQPISVQ KYSFITRKPDEVSRIYLFTAPFTVETWFCLMGIILLTAPTLYAI NRLAPLKEMRIVGLSTVKSCFWYIFGALLQQGGMYL PTADSGRLVVGFWWIVVIVLVTTYCGNLVAFLTFPKFQPGVD YLNQLEDHKDIVQYGLRNGTFFERYVQSTTREDFKHYL ERAKIYGSAQEEDIEAVKRGERINIDWRINLQLIVQRHFERDK ECRFALGRESFVDEQIAMIVPAQSAYLHLVNRHIKSM FRMGFIERWHQMNLPSAGKCNGKSAQRQVTNHKVNMDDM LGCFLVLLLGFTFALLIVCGEFWYRRFPASRKRRQFTN(SEQ IDNO:42) DsimIr93a MRQQFLVISAFHEDIIEIAETLNMFHVGNQWMIFVLDMVARD FDAGTVTINLDEGANIAFALNETEPNCQDSLNCTISEI SLALVDAISKITVEEESIYGEISDEEWEAIRFTKQEKQSEILGY MKEFLKTNAKCSSCARWRVETAITWGKSQENRKFRS TPQRDAKNRNFEFINIGYWTPVLGFVCQELAFPHIEHHFRNIT MDILTVHNPPWQILTKNSNGDIVEHKGIVMEIVKELS RALNFSYYLHEASSWKEEDSLSTSAGGNESDELVGSMTFRIP YRVVEMVQGNQFFIAAVAATLDDPDQKPFNYTQPISVQ KYSFITRKPDEVSRIYLFTAPFTVETWFCLMGIILLTAPTLYAI NRLAPLKEMRIVGLSTVKSCFWYIFGALLQQGGMYL PTADSGRLVVGFWWIVVIVLVTTYCGNLVAFLTFPKFQPGVD YLNQLEDHKDIVQYGLRNGTFFERYVQSTTREDFKHYL ERAKIYGSAQEEDIEAVKRGERINIDWRINLQLIVQRHFERDK ECRFALGRESFVDEQIAMIVPAQSAYLHLVNRHIKSM FRMGFIERWHQMNLPSAGKCNGKSAQRQVTNHKVNMDDM QGCFLVLLLGFTFALLIVCGEFWYRRFRASRKRRQFTN(SEQ IDNO:43) DvirIr93a MKEYLKANSKCASCAKWRFETAITWGKSQENRKFRMAPTR DTKNRNFEFINIGYWSPLLGFVCHELAFPHIDQHFRNITM DIVTVHNPPWQILTKDSRGAIVEHTGIVMEILKELSRALNFSY YLHEARSPDYEYSLAQSTNESDELMGSMTYRIPYRVV ELVQGSGYFMAAVAATIDEPHKKRFNYTQPISIQKYTFILRQP DEVSRIYLFTAPFTLETWGCLAGILLVTAPMLYIVNR LVPLQELQIRGLSTVKNCFWYIYGALLQQGGMYLPRADSGR LVVGFWWLVVIVLVTTYCGNLVAFLTFPKFQPGIDYLNQ LFDHKEIKQYGLRNGTFFEKYVHSTTRHDFKRFMERALVYN SSQSENIAAVKQGERINIDWRINLQLIVQQHFEQDKECR FALGKEDFVSEQIGLIVPSSSAYLHLINQHIDRLFRMGFIDRW HDTNLPSMDKCNGKHMQRQIANHKVNMDDMQGCFMVL LFGIIAALLVSCIEFWYYRFLVLNKGQSIAFAN(SEQIDNO: 44) DwilIr93a MPKHEQKHQQFLVISKFHEDIIEIAETLNMFHVSNQWMFFVL EELRRDFDASTVTINLDEGANIAFALNETYPDCQDTLN CTISEVSMALVTSISKMISEEQSIYGEISDEEWESIRFTKQEKQ DELLEYMKDYLKLNSKCASCARWRIDTAITWGKTQE SRQFRTAPTRDAKNRNFDFINIGYWSPLLGFVVQELTFPHIEH HFRNITMDILTVHNPPWQILTKNSLGHIVESKGIVME IVRELSRALNFTYQLHEAKSWEDEYAISQSKNESEMELLGSM TYRIPSRVTELAQGNQYFLAAVAATIYDPEKRFFNFTQ PISVQKYTFITRQPDEVSRIYLFTAPFTQETWGCLVGIIILTAPL LYGINRLAPLEELRIRGLSTIKSCFWYVLGALLQQ GGMYLPKADSGRLIVGFWWIVVIVLVTTYCGNLVAFLTFPK YQPGIDYLTQLAHHKHISQYGLRNGTFFEKYTKTTTRKD FKRFMEKAIIYNNAESERIDAVKSGQRINIDWRINLQLIVQQH FEQDKECHFALGKEDFVDEQIGLVVPLNSAYLHLINL HIDRMFRMGFIERWHQMNLPNSDKCNGKSVLRQITNHKVN MNDMQGCFLVLIFGFIVAVLVASIEFWYYRYHLHHQKRKQ SVFVN(SEQIDNO:45) DyakIr93a MRQQFLVISAFHEDIIEIAETLNMFHVGNQWMIFVLGMVGRD FDVGAATINLDEGANIAFALNETDPNCQDSLNCTISEL SLALVTSISKITVEEESIYGEISDEEWEAIRFTKQEKQAEILEY MKDYLKNNAKCSSCARWRVETATTWGKSQENRKFRS TPLRDAKNRNFEFINIGYWSPVLGFVCQELAFPHIEHHFRNIT MDILTVHNPPWQILTKNSHGVIVEHKGIVMEIVKELS RALNFSYYLHEASSWKEEYSLSTSAGSNESDELVGSMTFRIP YRVVEMVQGNQFFIAAVAATVEDSEQKPFNYTLPISVQ KYSFITRKPDEVSRIYLFTAPFTVETWFCLMGIILLTAPTLYAI NRLAPLKEMRIVGLSTVKSCFWYIFGALLQQGGMYL PTADSARLVVGFWWIVVIVLVTTYCGNLVAFLTFPKFQPGVD YLNQLANHKDIVQYGLRNGTFFERYVQSSTREDFKHYL ERARIYGSAQEEDIEAVKRGERINIDWRINLQLIVQRHFERDK ECRFALGKESFVDEQIAMIVPAKSAYLHLVNRHINSM FRMGFIERWHQMNLPSAGKCNGKSAQRQVTNHKVNMDDM QGCFLVLLLGFTVALLIVCGEFWCRRFRASRERRQFIN(SEQ IDNO:46) MrotIr93a MLSVLLLLWNVNYGNSFNDFPSLISTNVTMGTSLFSFLNDSY (Megachili YRSDRTITLINCLYYISDQAVVVDRSLFDSKEEYHNIA rotundata) GVIYDLITDTVKKEMQVGGIVVQVFRDGNVNLRQDYTILLSF ASCYLTWRLHEAAANKELMHLAITDPDCPRIPETDGLS VPLIMPGKELSQIFLDLRMTNILSWNVINILHDDTFDRDTISRV MKAISDKLPNRQLSLVSRSIFTLKHEDTEMARKKAV KKILDDFHVEQLGHCFLVIATVDMARSLRMVHPGSQWLYVV TNTAPNRTNITSFVELLAEGGNVAFIYNATDFNDFCEVK VTYYAKKLVQALAKALEYSLTNEIDMLKRVGGEDFEMIRLT KRERRKEILTNFKMYLERDVLNSETVHGRCVLWKFTSSI TWGNFFSHGKNVAHLLDIGTWTLAAGVITVNEKGERSYEGL VFDVINHLSKKLNFTYTVILPEVNSTKPWSSSRFSKLGD KINEMTMSNTRRVPKEVIKLVREKKVLLAACAYTVQEYEDTI NFTVPTWFCLAVTVIIMGPILYLIHKYSPYSTKTSGLN SSWQCVWYVYGALLQQGGMYLPQSDSARMLIGVWWLIVM VVVATYSGSLVAFLTFPKMDASILTVEDLIARKDKITWGFP NDSFLELYLRNTDEQKYQILLAYSERHNDTEEETFLMRKDLL LTGGCHFSLSADEFLDEPIAMIIPQDSPYLAESGLMNK WISEKMPMKDKCWEVPGSNQAVNKRKVNVADMQGIFFVLF MVWSVVVHGYDNVGFDGWYQPVPHRPVDIITDVINDLGVR ILQQYTSHGNVAFSPTGVAFVLAALYEGSAGRGRQQIADALG LPRDRDITRIGFRDIHRRLRTYLNANGFLGGLTLNQEN TNLRPEYEDILRFYGFDLSIPEDMNDTTIVPETEPTEKNIETET VTGTVPSTSTTPVETLGTMTADVQNRFTQTTLPSAM ESTVTVESTGAGETDVPEVSTMSSTTMASVTSPTTVPPVTLST TIAPATSPTTITPVTPITTISPVTSPTTISPVTSPTT ISPMTSPTTMSASTEPFMTTEDVLSTLTADDQPVTTQSSTSTS ASTSATTSALPMESTIPTDSTITTESGVTELPESTTT STITVPTTVNVMETSTSSTIPTQTGLPDVDANTVSTGSSNNQS VSDEIGSTDSPITTIIDTGETGSNEQTTVESTTSGTI NRRKRNIRAPRGFFSSYPDEGIWMQDLGIWKPYSSSLNEASV RDSTEISFLVNGCDVSSVTASRYIAVLPFAYFPSLHAV ALEFPLDVRIIFTVHNSGSWNVSNLSFQDPRYNILLMMSTDRR DTYRLARDLGGKSLRLLRKQLQATWVRATIPSFMLRG FLGILDVFEPRAADLSPMTPDLGVYARDVQQSIGVNIRNYMK PDRTHSRNGLFERAGPVPFTVVQPYLYFIIDAETSVTLIAGR (SEQIDNO:47) NvitIr93a MLLALLVLLAGWIEIGTGYNDFPSLMTANATMAVIVEKGFF (Nassonia KSADNYRHTLDEISDVANAVIRKNMEISGIALHVFGDAD vitripennis) VNLARDYTVLLSVASCQTTWHLFKRAQKEKLVYLAVTDPD CPRLPEDAGISLPLTNPGEELPQIFLDLRTTGSLSWPKVN LIHDDTFARDTISRVVKALSLELPDKRVSLSAQALFSTRFEKN ENAMRQRVHRILSNYHVDQLGSCFMVVVTVDMVSIVM EVAKSLRLVHPGSQWLYVISDAAGREAKVTSFAELLAEGEN VAFVHNATKHVANCNMGLMCHVKELVRALAISLENSLLN ELELYDRVTEEEFEVVRLSKAERKQEIVKSVNRELSYARAHT SSCGKCVNWRFSSAITWGTSFASSEEKQRRESGEKRRR ENSKRHSEDDLGEKSLGLGELLDAGTWSPGPGVNMSEPLFPH VEHGFRGRSLPVSTFHNPPWQIIKYSNTGAQEYGGLIF DVLNYLSLKLNFTYTVRLASSPAAEAPTRLPSAGDSSKSMDL AAMSVAQKVPQEVVELVRSKQVFIAASAFTVGKNSGGL NFTAAIVMQNYALLSAKPKPLSRALLFTAPYTNETWACLTSV LIVIGPILYLTVKLSPRPRDIDNSLSLSTTWQCSWYVY GALLQQGGMSLPKADSARLVIGTWWLVVMIVVATYSGNLIA FLTFPRIDAPIDNVDDLLARSDAFHWSFPNGSALESYLI AAVNDDPKYKQLLDGAERQDPSKPKQILDRVKAGNQVLID WRISLAFLMREDLIDTGGCHFHVSAEDFMHENMAMIISGD SPYLPLINDAIERMHESGLMKKWITEKMPMKDKCWEIAKTN QEATNHKVDMGDMQGIFFVLAIGFVIAAIAIGVEFAWHK RKEAFERSLIRPFVS(SEQIDNO:48) RproIr93a MYPKFRYFENKLKEIVNSRIHKFLDDGSLSVIYNGRDLKSKE (Rhodnius DLTAIFSITSCEEMWNLYSNFTGNGIIFITITEPDCPR prolixus) LPQHVGTTLPVYERGSEISQLILDLRSKEKLDWQSVTIVHDNS ISDKLVEKITLAVTKSLPITNSTCAISLYKIESSKND VDVKRNKEIFNTISSLPSLEINRNFLILAEVDIIPVVYESAKSVG LVDPTSKWLFIGMKTDFSNHNNINKFIHIVGDGEN VAFIYNSTDDTGLCLNNLLCHAEELVGNLAVALDYSIEEEIRL SEQVSDEEWEVIKPTKQERREAILNFMKNKQDDIGTC DNCTLWYFKSSESWGMDYFHKGNASLLEVGYWAPKPGPVL VDELFPNIVHGFRGRSIPIATFHYPPWQVIKYDDVGKPTE YKGLVFEIINELSNSLNFTYDVIIISNRTVLKSITNSLKIDEKLG EVSLDGRIETSAWKQALKLLENKRVLIAAAAFTVT EDRKKEVNFTYSISIEAYAFLVSRPKELSRALLFILPFSSDTWL CIIGAILLMTPLLCFVHRISPFYDHYSHRGKGGFTK MMNCFWYLYGALLQQGGGIMPEADSGRLVIGTWWLVVLV VVTTYSGNLVAFLTFPKMDKIISNVDQLMERRESLSWGMPE ISTLHSILKSTDNSKLNALSDGAKLHSKLTPEIISDIQNGKHIYI DRKTILAFVMKQEFIRTNRCDFSLGEEEFLEEHLA MALPVHTPYLKIFNSRIYEMHKVGLIQKWLVDYLPKRDKCW DAKLSGESNTHTVNMDDMQG(SEQIDNO:49) TurtIr93a MINHLFFLIYILLSPVSCQSNKDDSEQVINLGILIKYDDEISKAI (Tetranychus RNETLFHLIGEIESFSIDNITIKVDLIDGDSDFDA urticae) LVDGEPRNCNKYIGLISVLPCSLTKSLYSLIRDHCSSTLIIAIHD RNCIRPSRDQGIGFPILSSVDHVVPMLIDMRHDFL RKWDHINLIHDDTIDVMALHDLVDGLSAVHGPEIMPSTVTSY HIGLSLKNKIEITSDYRDINDSQVTLFSYENVKTDTLD LKAQVVDHITDEHKYFIVIAHSKHIKEIIKLAHSRSLLGSPRK WIFIFSDNQEDPAYWSQLSPILATTQTAIVIREESEY GRCSEMSEGCQFRLAVETLKSTLRKVALTADYDFTDVDMKR RTRNRLLTEMRLQLGSDESVSSRYCGNCDRYSLQMFEKA IIGESIKYKRKPYSTSHWSQTQFDDDFESGIKITRTGEWTPFKG LIQSSDPIPVDIVNGGGQVYKVGVVNQRPLVNVELI DGKCVVNGTTIELLTIISSRMNFTIEYVCWSDAKDDKIGDSIS DEGWDGLLGKLAEGKVDLAANGIWQTPSRIKSSAFEF LSAYDVDIVSLVVKKQPEDEKFLFIFNLSFSNIHLQQTWICVIL TMIVIGPVLWTVHRSSIYYDYYGLNDGKGFFKLSNC VWYCYGAMVQQGGDILPQAISGRVLIATWWLFVIVTVTTYS GNLVALLTFPKIIQPIQNAEDLANTWGVSAGAAASGALH EMIQILEYSELSLLRDKMSYYDFEKDKYKIFDEISSGSLGYLM TEYEARYWVSTEYTRTGVCGMHVARDAVYHTPIHMVA RKDAFPPSLLKELNRQMTLLTRAGIAIYWRLWYQTPGNDCM YPLIIHAGDVKKIDVVHMIGIYLFLACGIGIGFLILISE FITKYYISSDDDGLKMKTAKRQFSGSSGIQDVLKSIYTRYNAN PSYSKWASNVDYYNSAEGRSTGESKLVKLSFNHPTIN RDTKESFARSKWIQGASAVRAKASPNLYYDQFGPMYLNQIR GIYNDPDNFQYPFGGLRPK(SEQIDNO:50) Phlebotomus LIAIILDQEYLDQKYDPVYTEVQVIIERVLREDLKNGGLYVTY papatasi YSWTSVNLKKDYTAVLVVSNCDNTWRVFREARADTLLLLA LTDPDCPRLPPSEAIMVIPLTSGGEELPQVLLDLKSSQALKWK SAIVLHDDTFARDMISRVAIAVTSESPDGYVKPMSVSLFKIRA HIQEWERRKSIRRTLLSLPTNYIGRNFLAIVTTVIMENIMEVA KDLGMVEPFSQWMYVISDTNSERNNISSVLPLIGEGENVAFA YNVTSKDPACKAGITCHCAELLRSFVLALSRMIREEKAVYGQ ISDEEWETIRPTKKERRDMLLETMRLILKSTSVCSNCTTWKV QAGEYWGTEYEEEWSIVNTPRRSSKFLDVGTWKPNDGVQLN DVLFPHVSNGFRGKNLHIVTYHNPPWQIIAYNESGVPGVMRG VVMDILNEMAKKLNFTYTMHVIPVSIPKANETEELSYNVSST EEGQLPTTTIPMEILNLVSQDKVFLAAVGATVNEKYKRFINY TIPISIQPYNFIVSRPRELSRLYLFMAPFTKETWLCLAACIVVM GPLLYLVNRFSPFYEQKGFDIARLGLNRINNCFWYIYGALLQ QGNFWVGGMYLPQADSGRIIIGTWWLVVIVLVTTYCGNLVA FLTFPKIEIPITTVGQLVGKSGAVSWSTKSGTFLEEFLAETDEP KYKKLLDGMAFNTETSSDTIENVRQGKHVYIDWKSNLQYIM KKEFLVNDRCDFALGVEDFLDEQIAIIMPRDSAYLNLINSEITR LHQMGFIQRWLKEYLPKKDRCWNVGKAIEVNNHTVNLDDM QGSFLVLFIGCVLGACVIILECMWFKRRELKEQVIIKPFVK (SEQIDNO:51)
Variations of the Ir25a Receptor
(48) Homologs and Orthologs
(49) A homolog or an ortholog or any known or putative Ir25a receptor may also be used in the methods and systems described herein. A homolog may be a protein whose nucleic acid sequence that encodes that protein has a similar sequence to the nucleic acid sequence that encodes a known or putative Ir25a receptor, or a protein whose amino acid sequence is similar to the amino acid sequence of a known or putative Ir25a receptor. Ir25a homologs may have functional, structural or genomic similarities to any known or putative Ir25a receptor.
(50) In some embodiments, a homolog and/or ortholog of an Ir25a receptor is a protein whose nucleic acid sequences have at least 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the nucleic acid sequence encoding any known or putative Ir25a receptor. In another embodiment, a homolog of an Ir25a receptor is a protein whose amino acid sequence has at least 30%, 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the amino acid sequence encoding any known or putative Ir25a receptor.
(51) The Ir25a receptor may be from one or more arthropod species. For example, in certain embodiments, the Ir25a receptor is a homolog or ortholog of the Ir25a receptor from Drosophila melanogaster. In some embodiments, the Ir40a receptor has at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a polypeptide encoding an Ir25a receptor from Drosophila melanogaster. One of skill in the art will be able to readily identify Ir25a receptors, homologs thereof, and orthologs thereof that may be used in the methods and compositions of the present disclosure.
(52) While Drosophila melanogaster is one reference point for homology, it should be understood that other known or putative receptors may serve as reference points for homology to the Ir25a receptor. For example, known or putative Ir25a receptors may include Mayetiola destructor\Mdes015305, Aedes aegypti Aaeg\AAEL005012, Anopheles gambiae Agam\AGAP000256, Culex quinquefasciatus Cqui\ CPIJ009222, Heliconius melpomene\HMEL002270, Manduca sexta\Msex000431, Bombyx mori (Silkmoth) Bmor\BGIBMGA010960, Tribolium castaneium\TC000374, Atta cephalotes\ACEP27701, Acromyrmex echinatior\AECH20041, Solenopsis invicta\SINV12854, Pogonomyrmex barbatus\PB25907, Camponotus floridanus\CFLO19836, Linepithema humile\LH25937, Harpegnathos saltator\HSAL21373, Apis mellifera\GB42136, Apis mellifera\GB50521, Megachili rotundata\MROT 00005973, Nassonia vitripennis\Nasvi2EG001464, Acyrthosiphon pisum (Pea aphid) Apim\ACYPI20767,ACYPI43510, Rhodnius prolixus\RPTMP07829, Pediculus humanus (Human body louse) Phum\PHUM513120, Tetranychus urticae\tetur02g05540, and Ixodes scapularis\ISCW007957. Each sequence associated with the foregoing accession numbers is incorporated herein by reference.
(53) Modified Receptors
(54) In other embodiments, modified Ir40a receptors, modified Ir93a receptors, and/or modified Ir25a receptors may also be used in the methods and systems described herein. Modified polypeptides refer to polypeptides that have been altered relative to the endogenous sequence of the polypeptide in the organism from which they originated. Modifications may include, for example, deletion or addition of sequence information, attached of probes or molecular dyes to the polypeptide, or any other polypeptide modifications known in the art.
(55) A modified receptor, such as a modified Ir40a receptor, a modified Ir93a receptor, and/or a modified Ir25a receptor functions in a substantially similar fashion as an unmodified receptor, such as an unmodified Ir40a receptor, an unmodified Ir93a receptor, and/or an unmodified Ir25a. For example, a modification to an Ir40a, an Ir93a receptor, and/or an Ir25a receptor may include addition of sequence information to the full length polypeptide sequence, or removal of sequence information from the full length polypeptide sequence. In some embodiments, modified Ir40a receptors, modified Ir93a receptors, and/or modified Ir25a receptors may contain additional sequence information in the polypeptide. For example, a modified Ir40a receptor, a modified Ir93a receptor, and/or a modified Ir25a receptor may include reporter polypeptides such as GFP. In some embodiments, a modification to a receptor, such as modified Ir40a receptors, modified Ir93a receptors, and/or modified Ir25a receptors, may include a truncation of the receptor. Truncated receptors may include, for example, a polypeptide composed of a ligand-binding domain. In some embodiments, a modified receptor, such as modified Ir40a receptors, modified Ir93a receptors, and/or modified Ir25a receptors, may have both additional sequence information and deleted sequence information relative to the full-length polypeptide. For example, a modified Ir40a receptor may include a truncated Ir40a polypeptide composed of a ligand-binding domain fused to a reporter polypeptide, such as GFP.
(56) In some embodiments, modified Ir40a receptors, modified Ir93a receptors, and/or modified Ir25a receptors may also be used in the methods and systems described herein. Modified Ir93a receptors and/or modified Ir25a receptors may be used either alone or in any combination with a modified Ir25a receptor in the methods and compositions described herein.
(57) Arthropod Species
(58) Ir40a receptors, Ir93a receptors, and Ir25a receptors may be found in certain arthropods. One of skill in the art would recognize that arthropods are invertebrate animals characterized as having an exoskeleton, a segmented body, and jointed appendages. Arthropods belong to the Phylum Arthropoda under Kingdom Animalia. The Phylum of Arthropoda, or an arthropod, includes any invertebrate animal from the Classes of Insecta, Arachnida, Diplopoda, Chilopoda, Crustacea, and Xiphosura. In some embodiments, arthropod may refer to insects and arachnids that are exoparasitic sanguinivorous feeding pests, including any insect from the Order Diptera, such as mosquitoes, and any arachnid from the Order Ixodida, such as ticks. Examples of mosquitoes include Anopheles, Mimomyia, Culiseta, Orthopodomyia, Mansonia, Culex, Heizmannia, Aedes, Armigeres, Uranotaenia, Tripteroides, Topomyia, Malaya, and Toxorhynchite. As a specific type of such mosquito, an example of the Anopheles includes anopheles sinesis wiedemann. Examples of the Culex include Culex quinquefasciatus, Culex pipiens pallens, Culex pipiens molestus, and Culex tritaeniorhynchus. Examples of the Aedes include Aedes albopictus and Aedes aegypti. An example of the Armigeres includes Armigeres subalbatus.
(59) It should be understood that only certain arthropods have Ir40a receptors, Ir93a receptors, and/or Ir25a receptors. Ir40a receptors, Ir93a receptors, and Ir25a receptors are conserved in species such as Drosophila, mosquitoes, head lice; however, it is not present in the honey bee. Specific examples of arthropods which have an Ir40a, an Ir93a receptor, and/or an Ir25a receptor include Drosophila melanogaster, Drosophila grimshawi, Daphnia pulex, Anopheles gambiae, Zootermopsis nevadensis, Pediculus humanus, Acyrthosiphon pisum, Bombus terrestris, Harpegnathos saltator, Linepithema humile, Camponotus floridanus, Pogonomyrmex barbatus, Solenopsis invicta, Acromyrmex echinatior, Atta cephalotes, Tribolium castaneum, Bombyx mori, Aedes aegypti, Culex quinquefasciatus, Ixodes scapularis, and Mayetiola destructor.
(60) Additional Polypeptides
(61) Additional polypeptides may also be co-expressed with the Ir40a receptor, the Ir93a receptor, and/or the Ir25a receptor in a host cell or organism. These additional polypeptides may include, for example, a co-receptor, a chaperone protein, or any combinations thereof.
(62) Expression of a co-receptor to any one of the Ir40a receptors, Ir93a receptors, and/or Ir25a receptors described herein at the cell surface may enhance the respective receptor's sensitivity to volatile compounds, thus enhancing the sensitivity of the screening methods described herein. Expression of these additional polypeptides in addition to the ionotropic receptor may be beneficial with regards to enhancing receptor sensitivity without disrupting receptor specificity to a given compound/ligand. For example, an Ir25a receptor may be co-expressed with an Ir40a receptor in a host cell or organism. The Ir25a polypeptide may be recombinant to the host cell or organism. The Ir25a polypeptide may be a modified Ir25a receptor. In some embodiments, an Orco receptor may be co-expressed with an Ir40a receptor in a host cell or organism. The Orco polypeptide may be recombinant to the host cell or organism. The Orco polypeptide may be a modified Orco receptor.
(63) Expression of a chaperone in the Ir40a-expressing cell, an Ir93a-expressing cell, and/or an Ir25a-expressing cell may enhance the sensitivity of the screening methods described herein. Expression of these additional polypeptides in addition to the respective ionotropic receptor may be beneficial with regards to enhancing receptor sensitivity without disrupting receptor specificity to a given compound/ligand. In some embodiments, an RTP1 chaperone protein may be co-expressed with an Ir40a receptor in a host cell or organism. The RTP1 polypeptide may be recombinant to the host cell or organism. The RTP1 polypeptide may be a modified RTP1 polypeptide.
(64) Screening Assays
(65) In Vitro
(66) The methods described herein may be performed as part of an in vitro assay. For example, an isolated Ir40a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In other embodiments, an isolated Ir93a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In other embodiments, an isolated Ir25a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In other embodiments, an Ir40a receptor and an Ir93a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In other embodiments, an Ir40a receptor and an Ir25a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In other embodiments, an Ir93a receptor and an Ir25a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In other embodiments, an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor may be isolated and incubated with a candidate compound for use in an in vitro assay. In some embodiments, an Ir93a receptor and/or an Ir25a receptor may be isolated and incubated, either alone or in any combination with an Ir40a receptor, with a candidate compound for use in an in vitro assay. Incubation can be accomplished using any suitable methods known in the art.
(67) Any suitable in vitro assay format may be used. For example, an isolated Ir40a receptor, an isolated Ir93a receptor, and/or an isolated Ir25a receptor or a candidate compound may be non-diffusibly bound to an insoluble support having isolated sample-receiving areas such as a microtiter plate or an array. Suitable insoluble supports may include, for example, microtiter plates, arrays, membranes and beads. These supports may be made of glass, plastic (e.g., polystyrene), polysaccharides, nylon, or nitrocellulose, and similar materials. Additional methods for assembling in vitro activity assays will be apparent to those skilled in the art.
(68) Measuring in vitro activity of an isolated receptor, such as an isolated Ir40a receptor or modification thereof, an isolated Ir93a receptor or modification thereof, and/or an isolated Ir25a receptor or modification thereof, may involve incubating the one or more receptors with a radiolabeled compound. Methods of generating radiolabeled compounds are well known in the art, such as incorporation of radioactive carbon into the compound molecule. Measuring an interaction between the receptor and the radioactive compound, such as physical binding of the compound to the receptor, can be assayed using techniques such as gel shift mobility assays or measuring radiolabeled compound binding to the purified receptor in a plate or well.
(69) The Ir40a receptor, the Ir93a receptor, and/or the Ir25a receptor for use in in vitro assays may be isolated from a cell or an organism. One of skill in the art would recognize the methods and techniques for isolating and purifying polypeptides. The one or more isolated receptor polypeptides may be obtained, for example, by extraction from a natural source (e.g., an arthropod tissue or cell sample) by purification techniques such as centrifugation, column chromatography, polyacrylamide gel electrophoresis, and HPLC analysis; by expression of a recombinant nucleic acid encoding the receptor polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
(70) An isolated receptor generally refers to an isolated receptor substantially free of naturally-associated components (such as other proteins, lipids, or other cell membrane components) when it is separated from those naturally-associated components. For example, a polypeptide which is isolated and from a cell from which it naturally originates or is chemically synthesized or produced in a cellular system different from the cell from which it naturally originates (heterologous expression) will be substantially free from its naturally associated components.
(71) In Vivo
(72) The methods described herein may be performed as part of an in vivo assay. Organisms and cells expressing an Ir40a receptor or modification thereof, an Ir93a receptor or modification thereof, and/or an Ir25a receptor or modification thereof have been discussed above. Organisms and cells expressing an Ir93a receptor and/or an Ir25a receptor, expressed either alone or in any combination with an Ir40a receptor, may also be used herein. Methods of monitoring activity of a biological receptor in an in vivo system are well-known in the art.
(73) Measuring in vivo activity of an Ir40a receptor or modification thereof in an organism or in a cell may involve measuring electrophysiological parameters of the Ir40a receptor. Electrophysiological parameters may be measured both before and after contacting an Ir40a-expressing cell with a compound. Electrophysiological parameters may include measuring extracellular voltage or intracellular voltage, measuring potential changes, or similar parameters known in the art. Various methods of measuring electrophysiological parameters and/or measuring electrical potential changes are known in the art. Such methods may include, for example, the use of a patch clamp or the use of reporter nanoparticles or nanocrystals. Note that these methods of measuring electrophysiological parameters may also apply to measuring activity of an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with an Ir40a receptor.
(74) Measuring in vivo activity of an ionotropic receptor or modification thereof, such as a modified Ir40a receptor, Ir93a receptor, and/or Ir25a receptor, in an organism or in a cell may involve measuring changes in intracellular or extracellular ion levels. Ion levels may be measured both before and after contacting an Ir40a-expressing cell with a compound. Ions whose concentrations may be measured may include, for example, calcium, sodium, potassium, chloride, or any other ion which may serve as a proxy of Ir40a receptor activity. Methods of measuring the concentration of an ion in a cellular context are well known in the art and described herein. Measuring changes in intra- or extracellular ion concentration may involve using fluorescent voltage sensor dyes or other ion-specific molecular probes. Note that these methods of measuring in vivo activity of an ionotropic receptor may also apply to measuring activity of an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with an Ir40a receptor.
(75) Measuring in vivo activity of an Ir40a receptor or modification thereof in an organism or in a cell may involve measuring changes in transcription of activity-dependent gene promoters or directly assaying changes in transcription of genes. It is well known that the activity of ion channels, such as Ir40a receptors, in a cell can impact cellular gene expression. A modulated activity of an Ir40a receptor, such as in response to incubation with a compound, may impact the expression of one or more genes in the cell and this change in gene expression may be assayed using conventional techniques. Methods of monitoring gene expression in a cell may include quantitative reverse transcription polymerase chain reaction (qRT-PCR) and in situ hybridization. Additionally, changes in the expression of all genes may be assayed by generating whole-genome transcriptional profiles using next generation sequencing technologies, such as the Illumina sequencing platform. Note that these methods of measuring changes in transcription of activity-dependent gene promoters may also apply to measuring activity of an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with an Ir40a receptor.
(76) Screening Systems
(77) Provided herein are also systems used for identifying one or more compounds that are repellents for at least one arthropod species, based on modulation of the activity of an Ir40a receptor. Also provided herein are also systems used for identifying one or more compounds that are repellents for at least one arthropod species, based on modulation of the activity of an Ir93a receptor. Also herein are also systems used for identifying one or more compounds that are repellents for at least one arthropod species, based on modulation of the activity of an Ir25a receptor. Further provided herein are systems used for identifying one or more compounds that are repellents for at least one arthropod species, based on modulation of the activity of an Ir40a receptor, an Ir93a receptor, and/or an Ir25a receptor.
(78) In one embodiment, the system includes: a) a sample that includes an Ir40a receptor, an Ir93a receptor, and/or an Ir25a receptor; and one or more compounds that each is a repellent for at least one arthropod species, wherein the one or more compound each modulates the activity of the receptor. In certain embodiments, the receptor is an Ir40a receptor, and the system may further include an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with the Ir40a receptor. In certain embodiments, the receptor is an Ir93a receptor, and the system may further include an Ir25a receptor and/or an Ir40a receptor, either alone or in any combination with the Ir93a receptor. In certain embodiments, the receptor is an Ir25a receptor, and the system may further include an Ir93a receptor and/or an Ir40a receptor, either alone or in any combination with the Ir25a receptor.
(79) In another embodiment, the system includes: a) a sample that includes an Ir40a receptor, an Ir93a receptor, and/or an Ir25a receptor; and b) a plurality of candidate compounds, wherein at least one of the candidate compounds is a repellent for at least one arthropod species, and wherein the at least one repellent compound modulates the activity of the receptor. In certain embodiments, the receptor is an Ir40a receptor, and the system may further include an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with the Ir40a receptor. In certain embodiments, the receptor is an Ir93a receptor, and the system may further include an Ir25a receptor and/or an Ir40a receptor, either alone or in any combination with the Ir93a receptor. In certain embodiments, the receptor is an Ir25a receptor, and the system may further include an Ir93a receptor and/or an Ir40a receptor, either alone or in any combination with the Ir25a receptor.
(80) The sample may include a cell in which Ir40a, Ir93a, and/or Ir25a are expressed, as described above. The Ir40a receptor, Ir93a receptor, and/or Ir25a receptor may be provided with other polypeptides, such as co-receptor(s) and chaperone protein(s), in the sample. The system may include a cell in which an Ir93a receptor and/or an Ir25a receptor, either alone or in any combination with an Ir40a receptor, is expressed.
(81) Repellent Compounds and Compositions Thereof
(82) Provided herein are also the one or more compounds identified according to any of the methods or systems described herein.
(83) Compounds identified by the methods or systems described herein may be perceived by the olfactory system, or both the olfactory and gustatory systems. For example, with reference to
(84) The compounds identified by the methods or systems described herein modulate the activity of the Ir40a receptor, the Ir93a receptor, and/or the Ir25a receptor, either directly or indirectly. For example, some compounds may be ligands, binding to certain parts of the Ir40a receptor. Some compounds may be agonists of the Ir40a receptor, in which the agonist causes activation of the neuron downstream of the Ir40a. Additionally, some compounds may be ligands for or agonists of the Ir93a receptor and/or the Ir25a receptor.
(85) Compounds that activate Ir40a receptor, the Ir93a receptor, and/or the Ir25a receptor, alone or in combination, may be repellants for arthropods, such as flies (including Drosophila melanogaster) or mosquitoes. The arthropod repellents identified according to the methods or systems described herein may be formulated into a repellent for topical application, such as in the form of a lotion, cream, spray or dust. In some embodiments, the repellent may be included in, for example, a vaporizer, a treated mat, treated outerwear, an oil, a candle, or a wicked apparatus.
ENUMERATED EMBODIMENTS
(86) The following enumerated embodiments are representative of some aspects of the invention. 1. A method for identifying a compound that is a repellent for at least one arthropod species, comprising identifying a compound that modulates the activity of at least one receptor selected from the group consisting of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor. 2. The method of embodiment 1, wherein the at least one receptor is from an arthropod. 3. The method of embodiment 1 or 2, wherein the at least one receptor is from an insect. 4. The method of any one of embodiments 1 to 3, wherein the at least one receptor has at least 50% sequence identity to a polypeptide encoding a receptor from Drosophila melanogaster or an ortholog thereof. 5. The method of embodiment 4, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi. 6. The method of any one of embodiments 1 to 5, wherein the compound is identified in an in vitro assay or in vivo assay. 7. The method of any one of embodiments 1 to 6, wherein the modulation of the activity of the at least one receptor is determined by measuring changes in one or more electrophysiological parameters, measuring changes in calcium levels, measuring electrical potential changes, measuring changes in transcription of activity-dependent gene promoters, or any combination thereof. 8. The method of any one of embodiments 1 to 7, wherein the modulation in the activity of the at least one receptor is an increase in the activity of the at least one receptor. 9. The method of any one of embodiments 1 to 7, wherein the at least one receptor is an Ir40a receptor. 10. The method of embodiment 9, wherein modulation in the activity of the at least one receptor is an increase in the activity of the Ir40a receptor. 11. The method of embodiment 9 or 10, wherein the compound further modulates the activity of an Ir93a receptor. 12. The method of any one of embodiments 9 to 11, wherein the compound further modulates the activity of an Ir25a receptor. 13. The method of embodiment 9 or 10, wherein the compound further modulates the activity of an Ir93a receptor and an Ir25a receptor. 14. The method of any one of embodiments 1 to 7, wherein the receptor is an Ir93a receptor. 15. The method of embodiment 14, wherein modulation in the activity of the receptor is an increase in the activity of the Ir93a receptor. 16. The method of embodiment 14 or 15, wherein the compound further modulates the activity of an Ir25a receptor. 17. A method of identifying a compound that is a repellent for at least one arthropod species, comprising: a) contacting at least one receptor or a receptor-expressing neuron comprising at least one receptor with a candidate compound, wherein the at least one receptor is selected from the group consisting of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor; b) measuring the activity of the at least one receptor; c) comparing the activity of the at least one receptor after contact with the candidate compound to the activity of the at least one receptor in the absence of the candidate compound; and d) identifying a compound that is a repellent for at least one arthropod species by determining whether or not the candidate compound modulates the activity of the at least one receptor. 18. The method of embodiment 17 wherein the at least one receptor or receptor-expressing neuron is from an arthropod. 19. The method of embodiment 17 or 18, wherein the at least one receptor or receptor-expressing neuron is from an insect. 20. The method of any one of embodiments 17 to 19, wherein the at least one receptor has at least 50% sequence identity to a polypeptide encoding a receptor from Drosophila melanogaster or an ortholog thereof. 21. The method of embodiment 20, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi. 22. The method of any one of embodiments 17 to 21, wherein the at least one receptor or receptor-expressing neuron and the candidate compound are contacted in vitro or in vivo. 23. The method of any one of embodiments 17 to 22, wherein the at least one receptor is expressed in a cell. 24. The method of any one of embodiments 17 to 23, wherein the at least one receptor is expressed in an arthropod cell. 25. The method of any one of embodiments 17 to 24, wherein the at least one receptor is expressed in an insect cell. 26. The method of any one of embodiments 17 to 25, wherein the at least one receptor is expressed in a cell from Drosophila melanogaster or an ortholog thereof. 27. The method of any one of embodiments 17 to 26, wherein the at least one receptor is expressed in a neuron or an oocyte. 28. The method of any one of embodiments 17 to 27, wherein the at least one receptor is expressed in an isolated cell. 29. The method of any one of embodiments 17 to 28, wherein the at least one receptor is provided with a co-receptor or chaperone protein, or wherein the receptor-expressing neuron further expresses a co-receptor or chaperone protein. 30. The method of any one of embodiments 17 to 29, wherein the activity of the at least one receptor is measured by one or more electrophysiological parameters, calcium levels, electrical potential, transcription of activity-dependent gene promoters, or any combination thereof. 31. The method of any one of embodiments 17 to 30, wherein the modulation of the activity of the at least one receptor is an increase in the activity of the at least one receptor.
32. The method of any one of embodiments 17 to 31, wherein the at least one receptor is an Ir40a receptor. 33. The method of embodiment 32, wherein modulation of the activity of the at least one receptor is an increase in the activity of the Ir40a receptor. 34. The method of embodiment 32 or 33, wherein, in step (a), the candidate compound further contacts an Ir93a receptor. 35. The method of any one of embodiments 32 to 34, wherein, in step (a), the candidate compound further contacts an Ir25a receptor. 36. The method of embodiment 32 or 33, wherein in step (a), the candidate compound further contacts an Ir93a receptor and a an Ir25a receptor. 37. The method of any one of embodiments 17 to 30, wherein the receptor is an Ir93a receptor. 38. The method of embodiment 37, wherein modulation in the activity of the receptor is an increase in the activity of the Ir93a receptor. 39. The method of embodiment 37 or 38, wherein, in step (a), the candidate compound further contacts an Ir25a receptor. 40. A method of identifying a compound that is a repellent for at least one arthropod species, comprising: a) providing a sample comprising at least one full-length or partial receptor protein from Drosophila melanogaster or an ortholog thereof, wherein the at least one receptor protein is selected from the group consisting of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor; b) contacting the sample with a candidate compound; c) measuring the activity of the at least one receptor protein in the sample; d) comparing the activity of the at least one receptor protein after contact with the candidate compound to the activity of the at least one receptor protein in the absence of the candidate compound; and e) identifying a compound that is a repellent for at least one arthropod species by determining whether or not the candidate compound modulates the activity of the at least one receptor protein. 41. The method of embodiment 40, wherein the at least one receptor protein has at least 50% sequence identity to a polypeptide encoding the receptor from Drosophila melanogaster or an ortholog thereof. 42. The method of embodiment 41, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi. 43. The method of any one of embodiments 40 to 42, wherein the sample and the candidate compound are contacted in vitro or in vivo. 44. The method of any one of embodiments 40 to 43, wherein the sample further comprises a co-receptor or chaperone protein. 45. The method of any one of embodiments 40 to 44, wherein the activity of the at least one receptor protein is measured based on one or more electrophysiological parameters, calcium levels, electrical potential, transcription of activity-dependent gene promoters, or any combination thereof. 46. The method of any one of embodiments 40 to 45, wherein the modulation of the activity of the at least one receptor protein is an increase in the activity of the at least one receptor protein. 47. The method of any one of embodiments 40 to 45, wherein the at least one receptor protein is an Ir40a receptor. 48. The method of embodiment 47, wherein the modulation of the activity of the at least one receptor protein is an increase in the activity of the Ir40a receptor. 49. The method of embodiment 47 or 48, wherein the sample further comprises a full-length or partial Ir93a receptor protein from Drosophila melanogaster or an ortholog thereof. 50. The method of any one of embodiments 47 to 49, wherein the sample further comprises a full-length or partial Ir25a receptor protein from Drosophila melanogaster or an ortholog thereof. 51. The method of embodiment 47 or 48, wherein the sample further comprises a full-length or partial Ir93a receptor protein from Drosophila melanogaster or an ortholog thereof, and a full-length or partial Ir25a receptor protein from Drosophila melanogaster or an ortholog thereof. 52. The method of any one of embodiments 40 to 45, wherein the at least one receptor protein is an Ir93a receptor. 53. The method of embodiment 52, wherein modulation in the activity of the at least one receptor protein is an increase in the activity of the Ir93a receptor. 54. The method of embodiment 52 or 53, wherein the sample further comprises a full-length or partial Ir25a receptor protein from Drosophila melanogaster or an ortholog thereof. 55. A system, comprising: a) a sample comprising at least one receptor or a receptor-expressing neuron comprising at least one receptor, wherein the at least one receptor is selected from the group consisting of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor; and b) one or more compounds that each is a repellent for at least one arthropod species, wherein the one or more compounds each modulates the activity of the at least one receptor. 56. The system of embodiment 55, wherein the at least one receptor or receptor-expressing neuron is from an arthropod. 57. The system of embodiment 55 or 56, wherein the at least one receptor or receptor-expressing neuron is from an insect. 58. The system of any one of embodiments 55 to 57, wherein the at least one receptor has at least 50% sequence identity to a polypeptide encoding a receptor from Drosophila melanogaster or an ortholog thereof. 59. The system of embodiment 58, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi. 60. The system of any one of embodiments 55 to 59, wherein the at least one receptor is expressed in a cell. 61. The system of any one of embodiments 55 to 60, wherein the at least one receptor is expressed in an arthropod cell. 62. The system of any one of embodiments 55 to 61, wherein the at least one receptor is expressed in an insect cell. 63. The system of any one of embodiments 55 to 62, wherein the at least one receptor is expressed in a cell from Drosophila melanogaster or an ortholog thereof. 64. The system of any one of embodiments 55 to 63, wherein the at least one receptor is expressed in a neuron or an oocyte. 65. The system of any one of embodiments 55 to 64, wherein the at least one receptor is expressed in an isolated cell. 66. The system of any one of embodiments 55 to 65, the sample further comprises a co-receptor or chaperone protein. 67. The system of any one of embodiments 55 to 66, wherein the modulation of the activity of the at least one receptor or receptor-expressing neuron is an increase in the activity of the at least one receptor or receptor-expressing neuron. 68. The system of any one of embodiments 55 to 66, wherein the at least one receptor is an Ir40a receptor. 69. The system of embodiment 68, wherein modulation of the activity of the at least one receptor or receptor-expressing neuron is an increase in the activity of an Ir40a receptor or Ir40a receptor-expressing neuron. 70. The system of embodiment 68 or 69, wherein the sample further comprises an Ir93a receptor or the neuron co-expresses an Ir40a receptor and an Ir93a receptor. 71. The system of any one of embodiments 68 to 70, wherein the sample further comprises an Ir25a receptor or the neuron co-expresses an Ir40a receptor and an Ir25a receptor. 72. The system of embodiment 68 or 69, wherein the sample further comprises an Ir93a receptor, or the neuron co-expresses an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor. 73. The system of any one of embodiments 55 to 66, wherein the at least one receptor is an Ir93a receptor. 74. The system of embodiment 73, wherein modulation of the activity of the receptor or receptor-expressing neuron is an increase in the activity of an Ir93a receptor or Ir93a receptor-expressing neuron. 75. The system of embodiment 73 or 74, wherein the sample further comprises an Ir25a receptor or the neuron co-expresses an Ir93a receptor and an Ir25a receptor. 76. A system for screening a plurality of candidate compounds, comprising: a) a sample comprising at least one receptor or a receptor-expressing neuron comprising at least one receptor, wherein the at least one receptor is selected from the group consisting of an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor; and; and b) a plurality of candidate compounds, wherein at least one of the candidate compounds is a repellent for at least one arthropod species, and wherein the at least one repellent compound modulates the activity of the at least one receptor. 77. The system of embodiment 76, wherein the at least one receptor or receptor-expressing neuron is from an arthropod. 78. The system of embodiment 76 or 77, wherein the at least one receptor or receptor-expressing neuron is from an insect. 79. The system of any one of embodiments 76 to 78, wherein the at least one receptor has at least 50% sequence identity to a polypeptide encoding a receptor from Drosophila melanogaster or an ortholog thereof. 80. The system of embodiment 79, wherein the ortholog of Drosophila melanogaster is selected from the group consisting of Aedes aegypti, Anopheles gambiae, Culex quinquefasciatus, Acyrthosiphon pisum, Bombyx mori, Tribolium castenium, Pediculus humanus, Ixodes scapularis, and Phlebotomus papatasi. 81. The system of any one of embodiments 76 to 80, wherein the at least one receptor is expressed in a cell. 82. The system of any one of embodiments 76 to 81, wherein the at least one receptor is expressed in an arthropod cell. 83. The system of any one of embodiments 76 to 82, wherein the at least one receptor is expressed in an insect cell. 84. The system of any one of embodiments 76 to 83, wherein the at least one receptor is expressed in a cell from Drosophila melanogaster. 85. The system of any one of embodiments 76 to 84, wherein the at least one receptor is expressed in a neuron or an oocyte. 86. The system of any one of embodiments 76 to 85, wherein the at least one receptor is expressed in an isolated cell. 87. The system of any one of embodiments 76 to 86, wherein the sample further comprises a co-receptor or chaperone protein. 88. The system of any one of embodiments 76 to 87, wherein the modulation of the activity of the at least one receptor or receptor-expressing neuron is an increase in the activity of the at least one receptor or receptor-expressing neuron. 89. The system of any one of embodiments 76 to 87, wherein the at least one receptor is an Ir40a receptor. 90. The system of embodiment 89, wherein the modulation of the activity of the at least one receptor is an increase in the activity of the Ir40a receptor. 91. The system of embodiment 89 or 90, wherein the sample further comprises an Ir93a receptor or the neuron co-expresses an Ir40a receptor and an Ir93a receptor. 92. The system of any one of embodiments 89 to 91, wherein the sample further comprises an Ir25a receptor or the neuron co-expresses an Ir40a receptor and an Ir25a receptor. 93. The system of embodiment 89 or 90, wherein the sample further comprises an Ir93a receptor and an Ir25a receptor, or the neuron co-expresses an Ir40a receptor, an Ir93a receptor, and an Ir25a receptor. 94. The system of any one of embodiments 76 to 87, wherein the receptor is an Ir93a receptor. 95. The system of embodiment 94, wherein modulation of the activity of the at least one receptor or receptor-expressing neuron is an increase in the activity of an Ir93a receptor or Ir93a receptor-expressing neuron. 96. The system of embodiment 94 or 95, wherein the sample further comprises an Ir25a receptor or the neuron co-expresses an Ir93a receptor and an Ir25a receptor. 97. A composition comprising a compound identified according to the method of any one of embodiments 1 to 54.
EXAMPLES
(87) The following examples are merely illustrative and are not meant to limit any embodiments of the present disclosure in any way.
Example 1
Involvement of Ir40a Neurons in DEET Avoidance
(88) This Example demonstrates the involvement of the Ir40a+ Olfactory Sensory Neurons (OSNs) in DEET repellency.
(89) Materials and Methods
(90) Drosophila Olfactory Avoidance Assay for DEET:
(91) For each trial, three- to six-day old flies (10 males and 10 females) were starved for 18 hours. Flies were transferred to a cylindrical 38.1 mm D84.1 mm H chamber containing two traps each fashioned from an upturned 1.5 ml microcentrifuge tube with 2 mm removed from the tapered end. A pipette tip (1000 l), was cut 2.5 cm from narrow end and 0.5 cm from top and inserted into the bottom of the inverted microcentrifuge tube. A 15 mm16 mm #1 Whatmann filter paper was inserted in between the pipette tip and tip of microcentrifuge tube in a manner that entering flies cannot make physical contact with it. With reference to
(92) Results
(93) Synaptic transmission was blocked from Ir40a+ neurons using the Ir40a-promoter-Ga14 to express active form of tetanus toxin. A majority of control flies expressing a non-functional version of tetanus toxin (IMPTV) was observed to avoid DEET in the 1-choice trap assay lured by 10% apple cider vinegar (ACV) (
(94) The involvement of the Ir40a+ OSNs in DEET repellency was further investigated by silencing the Ir40a+ neurons using the Ir40a-promoter-Ga14 to express UAS-kir, an inward rectifying potassium channel. The two control lines showed a robust and reproducible avoidance response to volatile DEET in a 2-choice trap assay lured by 10% apple cider vinegar (ACV) (
Example 2
Involvement of Ir40a in DEET Avoidance
(95) This Example also demonstrates the involvement of the Ir40a receptor for DEET avoidance. Behavior assays (according to the protocol in Example 1) using mutant flies were performed. While no reported mutants or transposon insertion lines were available for Ir40a, two lines from the Drosophila Genome Reference Panel (DGRP) were identified that contain missense point mutations in Ir40a, which were confirmed by sequencing the appropriate portion of Ir40a in both lines (
Example 3
Behavior Experiments in Synaptic Activity Silenced Flies
(96) In order to investigate the involvement of the Ir40a+ neurons in mediating avoidance to newly discovered repellents, behavior experiments in synaptic activity silenced flies were performed as before (
Example 4
Involvement of Ir25a Receptor in DEET Avoidance
(97) This Example demonstrates the involvement of the Ir25a receptor in DEET avoidance. Behavior assays (according to the protocol in Example 1) were performed. Synaptic transmission was blocked from Ir25a+ neurons using the Ir25a-promoter-Ga14 to express an active form of tetanus toxin. A majority of control flies expressing a non-functional version of tetanus toxin (IMPTV) were observed to avoid DEET in the 1-choice trap assay lured by 10% apple cider vinegar (ACV) (
Example 5
Involvement of Ir25a and Ir93a Receptors in DEET Avoidance
(98) This Example demonstrates that the Ir93a and Ir25a receptors are involved in DEET avoidance. This Example also indicated that that the receptors Ir40a, Ir93a, and Ir25a may be involved in DEET avoidance. Behavior assays (according to the protocol in Example 1) were performed.
(99) Synaptic transmission was blocked from e Ir40a+ neurons using the Ir40a-promoter-Ga14 (Ir40a-G4) to express an active form of tetanus toxin (TNTG). A majority of control flies expressing either the Ir40a-promoter-Ga14 alone or the tetanus toxin alone (UAS-TNTG) was observed to avoid DEET in the 1-choice trap assay lured by 10% apple cider vinegar (ACV) (
(100) To test directly whether Ir40a is required for olfactory avoidance to DEET, the behaviour of flies in which Ir40a expression was decreased in Ir40a+ neurons was examined using the Ir40a-promoter-Ga14 (Ir40a-G4) with UAS-Ir40a-RNAi. In a 2-choice trap assay lured by 10% apple cider vinegar (ACV), a loss of DEET avoidance was observed in the Ir40a-RNAi flies as compared to control flies expressing either the Ir40a-promoter-Ga14 alone or the UAS-Ir40a-RNAi alone (
(101) The Ir40a+ neuron in the sacculus has previously been shown to express two other highly conserved Ir genes, Ir93a and a broadly expressed Ir25a (Benton, R., et al., Cell, 2009. 136(1): p. 149-62). Previously described receptor mutants of Ir93a and Ir25a receptors were each tested for their involvement in olfactory avoidance to DEET (